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Summary
The Mediator of transcriptional regulation is the central coactivator that
enables a response of RNA polymerase II to activators and repressors. It is
conserved from yeast to human and consists of 25 subunits in yeast that are
organized in four modules called head, middle, tail, and CDK8/Cyclin C module.
Despite its central role in transcription the functional mechanism remains enigmatic.
To overcome the lack of detailed structural data on the Mediator a recombinant
expression system was established that allows large-scale purifications of Mediator
head module subcomplexes. It has been shown that via limited proteolysis assays
and multicistronic expression the problems of insolubility and low expression rates of
Mediator subunits can be overcome, paving the way for structural studies on
subcomplexes of the Mediator head module. First data indicated that a reconstitution
of the complete head module is within close reach. Large-scale copurification data
led to a detailed interaction map of subunits and subcomplexes from within the head
module and towards the middle module.
The second part of this work describes the structure solution of a subunit in
the CDK8/Cyclin C module – Cyclin C. Cyclin C binds the cyclin-dependent kinases
CDK8 and CDK3, which regulate mRNA transcription and the cell cycle, respectively.
The crystal structure of Cyclin C reveals two canonical five-helix repeats and a
specific N-terminal helix. In contrast to other cyclins, the N-terminal helix is short,
mobile, and in an exposed position that allows for interactions with proteins other
than the CDKs. A model of the CDK8/Cyclin C pair reveals two regions in the
interface with apparently distinct roles. A conserved region explains promiscuous
binding of cyclin C to CDK8 and CDK3, and a non-conserved region may be
responsible for discrimination of CDK8 against other CDKs involved in transcription.
A conserved and Cyclin C-specific surface groove may recruit substrates near the
CDK8 active site. Activation of CDKs generally involves phosphorylation of a loop at
a threonine residue. In CDK8, this loop is longer and the threonine is absent
suggesting an alternative mechanism of activation is discussed based on a CDK8-
Cyclin C model.
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1
Introduction
1. Transcription and the Mediator
1.1. Gene transcription is accomplished by RNA polymerases
RNA synthesis, or transcription, is the process of transcribing DNA nucleotide
sequence information into RNA sequence information. RNA synthesis is catalyzed by
a large enzyme, the RNA polymerase. The process of gene transcription functions in
a very similar way in all life forms, thus was conserved over more than a billion years
of evolution. However, even though RNA synthesis itself, which is always catalyzed
by an RNA polymerase, might be quite similar – the central enzymes of all known
organisms share homologies (Ebright, 2000) – substantial differences are made in
the kingdoms of life on how to organize and regulate this process. In prokaryotes one
single RNA polymerase transcribes all RNA, whereas in eukaryotes (fungi and
metazoans) this task is carried out by three polymerase paralogs. RNA polymerase I
transcribes rRNA and RNA polymerase III tRNAs. All protein-coding genes are
transcribed by RNA polymerase II (RNA Pol II).
RNA synthesis takes place in three stages: initiation, elongation and
termination.  RNA synthesis is initiated at specific DNA sequences, so called
promoters. The prokaryotic E. coli RNA polymerase holoenzyme is a big 400 kD core
complex comprising 5 subunits (2x ", #, #́ , $), the initiation specific $-subunit can
dissociate from this holoenzyme, leaving a four subunit core enzyme (Young et al.,
2002). The core enzyme is responsible for template-directed RNA synthesis and also
interacts with regulatory proteins, which modulate transcription levels. The $-subunit
is responsible for the site-specific recognition of the promoter element as well as
melting of the promoter DNA. It is thought to dissociate and stay at the site of
transcription, facilitating transcription initiation by the next core enzyme. However,
new results implicate a role for the $-factor in elongation as well (Brodolin et al.,
2004; Mukhopadhyay et al., 2001). An additional level of gene regulation is
introduced by a multiplicity of $-factors that an E. coli cell possesses, each
responsible for a different set of promoters and genes.
Analogous to the prokaryotic system, transcription in eukaryotic cells is
initiated at promoters. Promoters for RNA Pol II typically contain a core sequence
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element, to which transcription factors bind and form a nucleation site for
transcription complex formation. The best-characterized, as well as most common
promoters in eukaryotes carry a TATA box as the core sequence element. The RNA
Pol II core enzyme consists of 12 subunits (513 kD). The structure of the RNA Pol II
core enzyme has been solved (Armache et al., 2005; Cramer et al., 2001) and
proved that RNA polymerases share a conserved core and common transcription
mechanism. The eukaryotic initiation factors, the general transcription factors (GTFs),
are more distantely related to the bacterial $-factor but function in a similar manner in
promoter recognition, promoter melting, abortive initiation and promoter escape
(Kornberg, 2005).
1.2. Initiation – starting the transcription cycle
The beginning of a round of transcription is marked by recruitment of the
transcription machinery to a promoter. The core promoter serves to position RNA Pol
II in the preinitiation complex (PIC). The bacterial equivalent to the PIC is called
closed complex.
Whereas in prokaryotes the $-factor is the only additional polypeptide required
for initiation, a number of additional factors are needed along with the core enzyme in
order to recognize the core element and initiate transcription in eukaryotes (Hahn,
2004). In vitro reconstitution of eukaryotic transcription by supplementation with
crude cell extracts, led to the identification of these factors (Weil et al., 1979). Since
factors from the crude extract had to be essential for transcription, fractionation and
purification of the exstract finally led to the identification of 5 essential GTFs: TFIIB,
TFIID, TFIIE, TFIIF, and TFIIH. A simplified model on how they enable transcription
in eukaryotes was established (Buratowski, 1994). The first step is promoter
recognition by TFIID — a multisubunit complex containing the TATA-binding protein
(TBP) and at least 14 tightly associated factors (TAFs) (Albright and Tjian, 2000;
Orphanides et al., 1996). Binding of TFIID causes bending of the DNA and serves as
an initial nucleation platform for further factors. TFIIB then binds to the platform and
stabilizes the complex by contacting TFIID and sequences flanking the TATA box on
both sides. TFIIB, in turn, recruits the RNA Pol II–TFIIF complex. However,
transcription cannot occur until TFIIE and TFIIH are incorporated, the PIC is formed.
ATP-dependent promoter melting leads to formation of the unstable open complex
where the DNA double helix is melted (“transcription bubble”) to facilitate the initiation
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of transcription. This step is catalyzed by the helicase activity of TFIIH. TFIIH as well
as TFIIE are also required for promoter escape of RNA Pol II (Hahn, 2004; Koleske
and Young, 1995; Kornberg, 2005; Thompson et al., 1993).
1.3. During the transcription cycle RNA Pol II undergoes regulatory
phosphorylation and dephosphorylation
The largest subunit of RNA Pol II comprises a carboxy-terminal repeat domain
(CTD) that consists in heptapeptide repeats of the consensus sequence
Y1S2P3T4S5P6S7. The CTD is unique to RNA Pol II. The number of repeats is species
dependent, and is 26 in yeast and 52 in human. At least eight repeats are required
for yeast viability (Nonet et al., 1987; West and Corden, 1995). The CTD, in particular
S2 and S5, is the target for regulatory phosphorylation and dephosphorylation during
the transcription cycle (Bentley, 2002). RNA Pol II is recruited to the promoter in a
hypophosphorylated state and becomes phosphorylated at S5 during transcription
initiation. Phosphorylation destabilizes the PIC leading to open complex formation
and promoter escape. During elongation Pol II becomes dephosphorylated on S5 and
phosphorylated on S2. Dephosphorylation on S2 enables entry into a new round of
transcription. The CTD acts as a platform for assembly of factors that regulate
transcription initiation, elongation, termination and mRNA processing (Hahn, 2004).
The central role of the CTD in mRNA synthesis is reflected by the fact that many
factors of the RNA Pol II transcription machinery bind the CTD, which is unique to
RNA Pol II.
1.4. Transcription needs regulation
In order to react to stimuli from the environment, a single cell needs to regulate
the production of proteins from a given set of genes. Cells in a multi-cellular organism
contain the same set of genes, but the subset of genes that are expressed
differentiates from one cell to another. Therefore gene expression must be regulated
in order to produce the right set of proteins in correct amounts at the right instant.
Regulation of gene expression is far more complex in eukaryotes than in prokaryotes
and takes place at many different levels, including transcription, RNA processing,
mRNA export, mRNA and protein stability and translation but also just recently
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discovered processes like RNAi and many more. The focal point in the regulation of
most genes is however the initiation of transcription at promoters.
RNA Pol II and GTFs alone can constitute in vitro basal transcription
(Conaway and Conaway, 1993; Roeder, 1996; Roeder, 1998). Transcriptional
regulation is achieved by elements both proximal and distal to the promoter that can
bind to regulatory factors and function in activation or repression of the
corresponding gene. A plethora of signals coming from the environment and
manifesting itselves in a variety of different activation and repression factors
somehow needs to be integrated and reduced to a simple switch for telling the
transcription machinery to start or to stay at the promoter. Thus a physical interaction
is required between a variety of signaling factors and a transcription machinery that is
highly conserved throughout the eukaryotic kingdom. In prokaryotic systems
transcriptional repressor and activator proteins bind to DNA sequences that are
adjacent to promoters and exert effects directly on RNA polymerase. While
repressors block binding of the polymerase to the promoter, activators increase its
affinity or stimulate open complex formation. In contrast to the bacterial system
regulatory proteins do not target the RNA polymerase directly (Kornberg, 2005). The
huge assembly of RNA Pol II and general transcription factors is unable to support
activated transcription by DNA-binding transcriptional activators in vitro (Myers and
Kornberg, 2000). This has led to the suggestion of intermediary factors, which
function as co-activators and are required for transmitting the variety of regulatory
signals produced in the cell from activators and repressors to the Pol II initiation
apparatus. The cofactors, co-activators as well as co-repressors, are thought to
assume this adapting role. They are distinct from GTFs since basal transcription in
vitro can function without their presence. In contrast to activators and repressors they
do not bind DNA with sequence specificity themselves (Roeder, 1998).
1.5. Discovery of a Mediator of transcriptional regulation in yeast
The Existence of an intermediary complex was first suggested when an
inhibitory effect called squelching was discovered in in vitro transcription assays. One
gene activator protein interfered with the effects of another in eukaryotic cells (Gill
and Ptashne, 1988). The effect remained even in the presence of large amounts of
GTFs. The target of activators could thus not be identical with the known basal
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transcription machinery. Interference could be reversed by a partially purified yeast
component, but not by RNA polymerase II or various polymerase II transcription
factors that was from crude extracts. It was suggested to be a novel factor, which
mediates the transcriptional activation process (Flanagan et al., 1991; Kelleher et al.,
1990).
Independently a genetic study led to the identification of mutations that
suppress the temperature sensitive phenotype of CTD truncations. They were named
srb for suppressor of RNAP B (Nonet and Young, 1989). At a later stage a complex
was discovered containing RNA Pol II, general transcription factors and some of the
Srb proteins. This complex was then termed the RNA Pol II holoenzyme, which could
support activated transcription in an in vitro system when supplemented with the
missing GTFs (Koleske and Young, 1994; Thompson et al., 1993). The different
activities and complexes that had been purified could be linked to one another when
a 20 subunit Mediator to homogeneity. The connection with the Srb- complex was
made by the finding that MED 20 (Srb2), (MED17) Srb4, (MED18) Srb5, and
(MED22) Srb6 were subunits of the pure Mediator (Kim et al., 1994).
Upon further purification the complex was shown to contain additional Srb
proteins, Srb8-11, now known as the CDK8/Cyclin C module (Liao et al., 1995).
Important functions have been ascribed to the Mediator: support of
transcriptional activation, stimulation of basal transcription and stimulation of TFIIH
dependent phosphorylation of the CTD (Kim et al., 1994; Myers et al., 1998). Later
Mediator was also shown to possess a histone acetyltransferase (HAT) activity
(Lorch et al., 2000). In fact, Mediator is needed for almost all RNA Pol II dependent
transcription in vivo (Holstege et al., 1998). It is a still ongoing discussion how the
preinitiation complex is assembled, which factors are present, and at which state
RNA Pol II is recruited.
1.6. Mediator functions in transcription initiation and reinitiation
It is not clear whether recruitment and assembly of the transcription machinery
at the promoter follows a sequential mode (Koleske and Young, 1995). Another
model is the recruitment of two complexes, a TBP containing complex and a
holoenzyme containing the remaining GTFs (Myer and Young, 1998). A spectrum of
possibilities might be realized at different promoters. It is known that transcription
initiation involves the interaction of the unphosphorylated CTD with the Mediator
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complex (Bjorklund and Gustafsson, 2004; Bjorklund and Gustafsson, 2005; Malik
and Roeder, 2000; Myers and Kornberg, 2000). The CTD is required for the
formation of stable RNA Pol II-Mediator complexes in yeast (Asturias et al., 1999;
Myers et al., 1998). Antibodies against the unphosphorylated CTD compete with this
interaction and therefore displace Mediator from Pol II (Kim et al., 1994; Svejstrup et
al., 1997). Consistent with its important central role in transcription initiation, binding
of Mediator to the CTD could also be shown for metazoan organisms (Jiang et al.,
1998; Naar et al., 2002; Park et al., 2001). The CTD-Mediator interaction is required
for Mediator function, since yeast Mediator cannot stimulate transcription by a CTD-
less Pol II (Myers et al., 1998).
The yeast Mediator binds cooperatively with Pol II and a subset of general
transcription factors at an intermediary state of PIC formation (Ranish et al., 1999). In
biochemical fractionation approximately 40% of Mediator forms a stable complex with
Pol II. On one hand this is consistent with studies showing that Mediator can be
recruited to promoters independent of the rest of the transcription machinery (Cosma
et al., 1999; Rani et al., 2004). On the other hand this might mean that RNA Pol II is
recruited to the promoter as the holoenzyme, with Mediator.
After initiation of Pol II transcription in vitro, many of the general transcription
factors remain behind at the promoter in the so-called scaffold complex (Yudkovsky
et al., 2000). The phosphorylated CTD does not associate with Mediator (Svejstrup et
al., 1997), and CTD phosphorylation during transcription initiation apparently also
breaks the Pol II-Mediator interaction, resulting in an elongating polymerase and a
scaffold complex where Mediator remains at the promoter (Liu et al., 2004). This
complex presumably marks genes that have been transcribed and enables the
typically slow step of recruitment to be bypassed in subsequent rounds of
transcription. Certain transcription activation domains can stabilize this scaffold
complex in vitro. The scaffold complex can then rapidly recruit the remaining general
transcription factors to promote transcription initiation.
Electron microscopic images of the yeast Pol II-Mediator complex suggest that
Mediator binds tightly to RNA Pol II at multiple interaction sites (Asturias et al., 1999),
presumably mainly the Rpb3 and Rpb11 subunits, on the side opposite to the active
site cleft (Davis et al., 2002). Figure 1 depicts the relative sizes of Mediator and RNA
Pol II and their suggested relative orientation. In addition, Mediator binds to several
general transcription factors involved in initiation (Kang et al., 2001; Park et al.,
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2001). Nevertheless, it remains enigmatic how the large 1MDa Mediator fits into the
context of the rest of the transcription machinery and by which mechanism it
transmits signals from regulatory factors to Pol II.
Fig.1 – RNA polymerase II and the relative size of Mediator
The complete 12-subunit yeast Pol II elongation complex structure (Armache et al., 2005;
Kettenberger et al., 2004) is shown as a ribbon diagram with the subunits in different colors.
DNA is in blue and RNA is in red. DNA and RNA outside the polymerase have been
extrapolated or modeled. The relative sizes of the yeast Pol II largest subunit linker region
and the CTD are indicated in green. The CTD is depicted in the putative state of a loose
spiral. Projections of Mediator consisting of head, middle, and tail module and of a
CDK/cyclin pair are drawn to scale.
1.7. Architecture of the Mediator
The Mediator subunit architecture was inferred from biochemical, genetic and
electron microscopic studies. Mediator was originally divided in two structural
submodules, MED17 (Srb4) and MED14 (Rgr1), after biochemical studies with urea
dissociation (Lee and Kim, 1998). Since a knockout of sin4 results in the loss of three
subunits including MED15 (Gal11) (Myers et al., 1998), the MED14 (Rgr1) module
was subdivided into the MED9/10 (Nut2) and the MED15 (Gal11) module (Kang et
al., 2001). The MED17, MED9/19 and MED15 modules were tentatively correlated
with three density lobes in electron microscopic images, termed the head, middle,
and tail module, respectively (Dotson et al., 2000).
The biochemically defined MED15 (Gal11) module could be assigned to the
tail using again the Sin4 knockout (Dotson et al., 2000). MED15 (Gal11) and MED10
(Nut2) both interact with MED14 (Rgr1), it was thus clear that the MED10 (Nut2)
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protein must belong to the middle domain (Li et al., 1995). As an indirect conclusion,
the MED17 (Srb4) module was assigned to be the head module.
EM pictures suggest that the head module is the major RNA Pol II-interacting
subcomplex while the middle module seems to make fewer contacts. The head and
middle modules form a core Mediator that can be isolated from yeast (Liu et al.,
2001; Myers et al., 1998). Core Mediator enables 4-fold activation of transcription in
nuclear extracts, compared to 18-fold activation for the complete Mediator. The CTD
may bind between the head and middle modules, since the Srb proteins are
distributed among head and middle module and since recombinant head and middle
modules independently bind to the CTD (Kang et al., 2001).
The EM pictures do apparently not contain the CDK8/Cyclin C module. The
additional Srb proteins 8-11(Table 1) (Liao et al., 1995; Nonet and Young, 1989) can
be found in some holoenzyme preparations (Myer and Young, 1998). However, its
presence depends on the preparation protocol, it has been suggested to be
associated to present in the holoenzyme of cells growing exponentially and absent
from cells in the stationary phase (Hengartner et al., 1998).
Various lines of evidence suggest that the tail module – MED15 (Gal11),
MED2 and MED3 (Pgd1) and Sin4 (Myers et al., 1998) (Table1) – is the main target
for transcriptional activators. The holoenzyme isolated from gal11 null mutant lacks
the entire tail MED15 (GAL11) module and is functionally defective for activated, but
not basal transcription (Han et al., 1999; Park et al., 2000) Binding assays in vitro
show binding of activators to Mediator through the MED15 (GAL11) module (Lee et
al., 1999b).
Half of the subunits in the MED17 (Srb4) subcomplex, that is thought to form
the head module of the Mediator, consist in Srb-proteins, namely MED20 (Srb2),
MED17 (Srb4), MED18 (Srb5), MED22 (Srb6). The other four subunits are named
Med6, Med8, MED19 (Rox3) and Med11 (Table 1). The 8 subunits interact with one
another as shown by a variety of in vitro experiments (Kang et al., 2001; Lee and
Kim, 1998). In particular it was shown that it is possible to purify the MED17 (Srb4)
complex after recombinant expression in a baculoviral system (Koh et al., 1998).
The most conserved part of Mediator is the middle module (Baumli et al.,
2005), which comprises subunits MED7, MED21, MED10, MED1, MED4, MED9, and
possibly MED31 (Table1). With the exception of MED31 (Soh1), that was shown to
Introduction
9
be part of the Mediator only recently (Guglielmi et al., 2004; Linder and Gustafsson,
2004), MED7 and MED21 show the highest degree of sequence homology of all core
Mediator subunits (40% and 45% between yeast and human, respectively). This high
conservation is reflected in their essential function in yeast (Myers et al., 1998) and in
a requirement for MED21 in mouse development (Tudor et al., 1999).
Electron microscopy also showed that Mediator undergoes strong structural
changes upon interaction with Pol II (Asturias et al., 1999; Davis et al., 2002; Naar et
al., 2002) and with transcription activators (Taatjes et al., 2002) that are obvious even
at 35 Å resolution (Davis et al., 2002). The causes and consequences of these
changes are however poorly understood, and the molecular mechanism of Mediator
remains enigmatic. Recently the structure of the MED7/Srb7 heterodimer in the
middle module was solved (Baumli et al., 2005). The important role that the huge
conformational changes might have for function of Mediator is reflected in highly
conserved elements that confer flexibility. Such hinges could provide a mechanistic
principle, which could underlie Mediator function.
1.8. A unified nomenclature for Mediator proteins
Counterparts of the S. cerevisisae Mediator have been identified in many
higher organisms. Biochemical and bioinformatical methods finally led to
understanding that Mediator is conserved from yeast to human (Boube et al., 2002;
Bourbon et al., 2004). Several Mediator complexes have been identified from
mammalian cells: thyroid hormone receptor-associated proteins (TRAP) (Fondell et
al., 1996; Fondell et al., 1999), suppressor of RNA polymerase B (SRB)-mediator
containing cofactor (SmCC) (Gu et al., 1999), activator-recruited cofactor (ARC)
(Naar et al., 1999), vitamin D receptor-interacting proteins (DRIP) (Rachez et al.,
1999), negative regulator of activation transcription (NAT) (Sun et al., 1998), positive
cofactor 2 (PC2) (Kretzschmar et al., 1994; Meisterernst et al., 1991), and cofactor
required for Sp1 activation (CRSP) (Ryu and Tjian, 1999; Ryu et al., 1999). Tandem
mass spectrometry was used to systematically identify the proteins present in the
highly purified complexes and to differentiate between 30 MED subunits (MEDs)
(Sato et al., 2003; Tomomori-Sato et al., 2004). While initially only 8 subunits of
Mediator were thought to be conserved over evolution (Malik and Roeder, 2000;
Rachez and Freedman, 2001) it became clear after extensive cross species
comparisons that counterparts for nearly every yeast Mediator subunit could be
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found in metazoans (Borggrefe et al., 2002; Boube et al., 2002; Gustafsson and
Samuelsson, 2001; Samuelsen et al., 2003). Consequently in 2004 it was proposed
for reasons of simplicity and easier understanding to introduce a unified
nomenclature for Mediator subunits in all species, acknowledging conservation from
yeast to human. All known subunits are named from MED1 to MED31, except CDK8
and CycC (Cyclin C) (table 1). The original names however carry implications for the
function of these proteins.
Table 1- Unified nomenclature of the Mediator subunits
New name in all
species
S. cerevisiae-
previous name
New name in all
species
S. cerevisiae-
previous name
Head Tail
MED6 Med6 MED2 Med2
MED8 Med8 MED3 Pgd1/Hrs1/Med3
MED11 Med11 MED5 Nut1
MED17 Srb4 MED15 Gal11
MED18 Srb5 MED 16 Sin4
MED 19 Rox3
MED20 Srb2 CDK8/Cyclin C
MED22 Srb6 CDK8 Srb10/Ssn3/Ume5
CycC Srb11/Ssn8/Ume3
Middle MED12 Srb8
MED1 Med1 MED13 Ssn2/Srb9
MED4 Med4
MED7 Med7
MED9 Cse2/Med9
MED10 Nut2/Med10
MED14  Rgr1
MED21 Srb7
MED31 Soh1
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2. The Mediator CDK8/Cyclin C Module
2.1. CDK-cyclin pairs
Cyclin-dependent kinases (CDKs) associate with specific cyclins and play
central roles in cell cycle regulation and transcription (Bregman et al., 2000;
Dynlacht, 1997; Murray, 2004). Phosphorylation is the major posttranslational
modification of the CTD in vivo. The correct phosphorylation status of the CTD of
RNA Pol II is required for initiation, repression and successful elongation of
transcription (Bensaude et al., 1999; Cadena and Dahmus, 1987; Kang and Dahmus,
1993; Lu et al., 1992) but also plays an important role in mRNA capping, mRNA
polyadenylation, and mRNA export. It is likely that the CTD recruits components of
the splicing machinery to the RNA polymerase II elongation complex (Shilatifard et
al., 2003).
The specific phosphorylation status of the CTD is achieved by a number of
kinases and phosphatases and big effort has been put in investigating the nature of
the CTD kinases. While a large number of kinases was identified to phosphorylate
the CTD in vitro, one group of kinases has been well established so far to be of
crucial functional relevance in controlling/running the transcription cycle in vivo: the
highly conserved paralogs of CDK7, CDK8 and CDK9, which form part of TFIIH, of
Mediator, and of the Positive Transcription Elongation Factor b (P-TEFb)
respectively, are implicated in key roles of the transcription cycle.
CDKs were originally found to be a family of kinases whose activity and
thereby control over the cell cycle is driven by the fluctuating abundance of their
regulatory cyclin subunit (Lees, 1995; Morgan, 1995). They all share a high degree of
conservation that is reflected in a very similar fold (Lolli et al., 2004; Russo et al.,
1996; Russo et al., 1998; Tarricone et al., 2001). However, conservation levels differ
more strongly in the cyclin subunits. The CTD kinases CDK7, CDK8 and CDK9
associate with C- type cyclins, a subfamily that was first identified as a more distantly
related group of cyclins (Leopold and O'Farrell, 1991; Lew et al., 1991): Cyclin H
(THIIH), Cyclin C and Cyclin T (T for transcription). Despite their name, these cyclins
do not show major fluctuation in abundance throughout the cell cycle, clearly
separating therefore the regulation and role of the CTD kinases from classical cell
cycle CDKs (Adamczewski et al., 1996; Garriga et al., 1998; Nigg, 1996; Rickert et
al., 1996; Tassan et al., 1994). Nevertheless, there are many clues to a link between
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transcription and the cell cycle through these kinases (Edwards et al., 1998; Fu et al.,
1999; Nishiwaki et al., 2000; Ren and Rollins, 2004; Sage, 2004).
2.2. Three CDKs differentially phosphorylate the CTD and regulate
transcription
2.2.1. CDK7/Cyclin H
The specificity of CDK7/Cyclin H for the CTD seems to depend on the
association with higher order complexes. The CDK/cyclin pair for itself and in
complex with a third protein – ménage a trois –, the MAT1 RING finger protein forms
the so-called CAK, the CDK activating kinase, which phosphorylates other CDKs and
thereby activates them during cell cycle (Devault et al., 1995; Fisher et al., 1995;
Harper and Elledge, 1998; Larochelle et al., 1998; Wallenfang and Seydoux, 2002).
The affinity towards the CTD is increased when this trimeric complex is part of the
general transcription factor TFIIH (Rossignol et al., 1997; Yankulov and Bentley,
1997) and the substrate specificity towards the CTD phosphorylation is highest when
TFIIH is part of the RNAPII and GTF containing initiation complex (Lu et al., 1992;
Watanabe et al., 2000). Phosphorylation of the CTD by CDK7 during initiation leads
to promoter escape. Kin28 has been proposed to be the primary CTD kinase at
initiation in vivo (Komarnitsky et al., 2000; Liu et al., 2004; Schroeder et al., 2000;
Valay et al., 1995). TFIIH has at least three functions in transcription: ATP-dependent
promoter DNA opening by its helicase activities, CTD phosphorylation and
suppression of arrest of early RNAPII elongation complexes (Oelgeschlager, 2002).
In S. cerevisiae the CDK7 ortholog Kin28 is apparently less linked to the cell cycle
since it exhibits no CAK activity, which instead is mediated by a different CDK
activating kinase, Cak1 (Kaldis et al., 1996). S. pombe possesses two CAKs
(Hermand et al., 1998; Lee et al., 1999a; Molz and Beach, 1993). Kin28 is the kinase
present in TFIIH in S. cerevisiae and is required for normal levels of transcripts in
vivo (Holstege et al., 1998). The kinase activity of Kin28 is essential for viability (Liu
et al., 2004).
2.2.2. CDK8/Cyclin C
The CDK8/Cyclin C pair (or Srb10/Srb11) was discovered in yeast and human
cells (Liao et al., 1995; Tassan et al., 1995). As described above CDK8/Cyclin C
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associates with MED12 (Srb8) and MED13 (Srb9), to form a fourth module of the
Mediator of transcriptional regulation, the CDK8/Cyclin C module. This module is
present in a subpopulation of the Mediator, is conserved among eukaryotes, and
phosphorylates the Pol II CTD (Borggrefe et al., 2002; Boube et al., 2002; Liu et al.,
2001; Samuelsen et al., 2003). As CDK7, CDK8 is found tightly associated with the
preinitiation complex (Liu et al., 2001; Orphanides et al., 1996; Ranish et al., 1999).
The first identification of this kinase had already linked it to RNAPII transcription and
the CTD. It was cloned together with the mentioned srb genes as suppressors of a
temperature sensitive phenotype caused by truncations of the CTD (Koleske et al.,
1992; Koleske and Young, 1994; Thompson et al., 1993) and turned out to form large
parts of the Mediator complex. The CDK8/Cyclin C module is a target of the Ras/PKA
signal transduction pathway (Chang et al., 2004) and is moreover involved in Notch
signaling (Fryer et al., 2004). The role of phosphorylation by CDK8 in transcription
still remains enigmatic. An appealing model is the function as a repressor of
transcriptional initiation: formation of the preinitiation complex could be prevented
through premature phosphorylation of the CTD (Hengartner et al., 1998). On the
other hand a recent study points out an overlapping function of CDK7 and CDK8 in
vivo, with the essential CDK7 being the more dominant kinase masking in vivo
effects of a CDK8 deletion (Liu et al., 2004). Upon deletion of this kinase several
genes are derepressed and many others are repressed, but it is still unclear whether
this effect of repression is direct or indirect. There are also many other potential
substrates involved in transcription that are targets of CDK8, such as activators, like
Gal4 and Sip4 (Ansari et al., 2002; Vincent et al., 2001), and the factors Gcn4 and
Ste12, which are destabilized upon phosphorylation (Chi et al., 2001; Nelson et al.,
2003). CDK8 binds the Gal4 activation domain (Ansari et al., 2002). CDK8 promotes
ATP-dependent dissociation of preinitiation complexes, resulting in a positive effect
on transcription (Liu et al., 2004). CDK8/Cyclin C phosphorylates subunits of the
general transcription factor TFIID (Liu et al., 2004), and the Mediator subunit MED2
(Hallberg et al., 2004). Mutation of the MED2 phosphorylation site reduces
expression levels of certain genes (Hallberg et al., 2004). The role of the binding
partners within the CDK8/Cyclin C module for recruiting the kinase and thereby
influencing substrate specificity remains to be eluted.
As for CDK7, also for CDK8/CyclinC an additional role in the cell cycle has
been implicated. Human CDK8 is able to inactivate CDK7 through phosphorylation
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and might therefore repress its CDK activating activity as well as transcription
(Akoulitchev et al., 2000). The regulatory Cyclin C, which had originally been
identified to perform a role in G1/S transition (Leopold and O'Farrell, 1991; Lew et al.,
1991), was recently shown to play a role in the cell cycle by association with CDK3 in
human cells (Ren and Rollins, 2004; Sage, 2004). Cyclin C could also play a second
role in transcription through association with CDK11, a recently characterized kinase
that coordinates transcription and RNA processing (Hu et al., 2003; Trembley et al.,
2003).
2.2.3. CDK9/Cyclin T
P-TEFb had originally been identified in metazoans as a heterodimer of CDK9
with one of the cyclin T isoforms T1, T2, or K (Peng et al., 1998). A larger P-TEFb
complex with reduced activity additionally contains the small nuclear RNA 7SK and
the HEXIM protein (Michels et al., 2003; Nguyen et al., 2001; Yang et al., 2001; Yik
et al., 2003). P-TEFb was isolated by the ability to overcome arrest by RNAPII
complexes in early elongation (Marshall and Price, 1995) and its role in
phosphorylating the CTD is implied by the fact that in vitro this only occurs when the
CTD is present on RNAPII (Marshall et al., 1996).
 P-TEFb is thought to function in a dual way through its effect on 5,6-dichloro-
1-beta-d-ribofuranosylbenzimidazole (DRB) sensitivity inducing factors (DSIF) and
the negative elongation factor (NELF), which repress early elongation by interacting
with hypophosphorylated RNA Pol II. On one hand P-TEFb could act through
transition from the hypophosphorylated to the hyperphosphorylated RNA Pol II form
and on the other hand directly act upon DSIF, which can be phosphorylated by CDK9
on its Spt5 subunit (Wada et al., 1998a; Wada et al., 1998b; Yamaguchi et al.,
1999a; Yamaguchi et al., 1998; Yamaguchi et al., 1999b).
CTD kinase 1 (CTDK1) and Bur1/Bur2 are the two closely related CDKs that
could in S. cerevisiae comprise a similar function as P-TEFb (Guo and Stiller, 2004;
Lee and Greenleaf, 1991; Murray et al., 2001; Prelich and Winston, 1993; Sterner et
al., 1995). While Bur1/Bur2 represent a CDK and its cyclin, CTDK1 consists, similar
to the other CTD kinases, of an additional subunit: it is composed of three subunits:
Ctk1, Ctk2 and Ctk3 (Carboxy Terminal Domain kinase). Bur1 was suggested to be
the specific ortholog of CDK9 after computational analysis (Guo and Stiller, 2004).
Chromatin immunoprecipitation (ChIP) and genetic data suggest that the two kinases
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do not overlap in their function but both play a crucial role in elongation (Cho et al.,
2001; Keogh et al., 2003; Yao et al., 2000; Yao and Prelich, 2002). While Bur1 is
essential Ctk1 is not (Lee and Greenleaf, 1991; Prelich, 2002). It was recently
suggested (Keogh et al., 2003) that Ctk1 might have the CTD as a substrate, while
Bur1 phosphorylates Spt4/5: Bur1/2 share a number of phenotypes with spt4/5/6
deletions (Happel et al., 1991; Neigeborn et al., 1987; Prelich and Winston, 1993;
Swanson et al., 1991; Swanson and Winston, 1992) and Spt5 contains several
sequence motifs reminiscent of the CTD heptapeptide (Keogh et al., 2003). This
model is particularly appealing since the situation would be similar to another split
kinase function in yeast: S. cerevisiae also has two kinases for CAK activity and CTD
phosphorylation by TFIIH, instead of one, as for example in the human system.
2.2.4. Substrate specificity and regulation of CTD kinases
Phosphorylation occurs mainly at Ser2 and Ser5 (Corden et al., 1985) with
around 50 phosphates groups in the hyperphosphorylated RNA Pol II form, an
average of one per repeat (Payne and Dahmus, 1993). More Ser5 phosphorylation
has been observed in promoter proximal regions, Ser2 phosphorylation
predominates in more distal regions and triggers binding of the 3´-RNA processing
machinery (Cho et al., 2001; Komarnitsky et al., 2000). Ser5 phosphorylation recruits
and activates the mRNA capping machinery (Cho et al., 1997; Ho et al., 1998;
Komarnitsky et al., 2000; McCracken et al., 1997). The CDKs involved in CTD
phosphorylation differ in their specificity towards the target serine residue. CDK7 and
CDK8 phosphorylate S5, whereas CDK9/Ctk1/Bur1 phosphorylates S2, although
depending on the assay used, the length of the peptide, and detection mechanism
different results have been obtained (Table 2). Thus CDK7 activity predominates
during initiation, whereas CDK9 activity is important during elongation (Cho et al.,
2001; Kim et al., 2002; Komarnitsky et al., 2000). CDK7 and CDK8, but not Bur1 or
Ctk1, are stably associated with transcription initiation complexes (Liu et al., 2004).
CDKs also differ in their processivity. CDK7 generates hyperphosphorylated CTD
peptides, whereas CDK8 and CDK9 generate CTD peptides with fewer
phosphorylations (Pinhero et al., 2004). A few principles underlying CTD
phoshorylation state recognition have been suggested (Meinhart and Cramer, 2004;
Meinhart et al., 2005).
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Kinase specificity for the CTD may not only be achieved by CTD recognition at
the kinase active site, but also by CTD binding to kinase-associated factors. The
preference of TFIIH for S5 phosphorylation is enforced by TFIIE (Yamamoto et al.,
2001). The HIV Tat protein shifts CDK9 phosphorylation preference from S2 to both
S2 and S5 (Zhou et al., 2000). Cyclin A has a conserved surface patch that binds
kinase substrates (Kontopidis et al., 2003; Schulman et al., 1998). Cyclin T binds the
CTD via a histidine-rich stretch in its C-terminal domain (Kurosu et al., 2004; Taube
et al., 2002). A recent study suggests that the cyclins generally act as adaptors to
render a CDK specific for a substrate (Loog and Morgan, 2005).
Table 2 – Specificity of CTD kinases
CTD kinase S2 phosphorylation S5 phosphorylation Reference
CDK7 + (Rickert et al., 1999)
+ (Trigon et al., 1998)
(+) (Dubois et al., 1997;
Patturajan et al., 1998)
+ (Zhou et al., 2000)
+ (Ramanathan et al.,
2001)
+ (Sun et al., 1998)
+ + (Watanabe et al., 2000;
Yamamoto et al., 2001)
+ (Kim et al., 2002)
(+) + (Komarnitsky et al., 2000)
+ (Hengartner et al., 1998)
CDK8 + + (Sun et al., 1998)
+ (Rickert et al., 1999)
+ (Ramanathan et al.,
2001)
+ (Hengartner et al., 1998)
+ + (Borggrefe et al., 2002)
CDK9 + (+) (Komarnitsky et al., 2000)
+ (+) (Zhou et al., 2000)
+ (Ramanathan et al.,
2001; Ramanathan et al.,
1999)
+ (Shim et al., 2002)
+ (Kim et al., 2002)
Ctk1 + (Dubois et al., 1997;
Patturajan et al., 1998)
+ (Cho et al., 2001)
+ + (Jones et al., 2004)
Bur1 + (Murray et al., 2001)
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An open question is the activation mechanism of the CTD-targeting CDKs.
CDKs involved in cell cycle regulation are generally activated in two steps, cyclin
binding, and phosphorylation of a conserved threonine in the CDK activation
segment (T160 in human CDK2) (Pavletich, 1999). Interaction of the
phosphothreonine side chain with three conserved arginines triggers a
conformational change that results in full kinase activation (Russo et al., 1996).
CDK7 and CDK9 carry a threonine or a serine at the phosphorylated position. In the
free CDK7 structure, the phosphorylated threonine however is found at a different
location than in CDK2 (Lolli et al., 2004), and does not contact the three conserved
arginines, pointing to a different mechanism of CDK activation. Also, CDK8 does not
have a threonine or serine residue at the position phosphorylated in other CDKs
(Tassan et al., 1995).
Structural information about the CTD kinases, compared to other CDKs and
cyclins, helps to shed light on their regulation mechanisms. The structure of Cyclin H
revealed a difference to other known cyclin structures (Andersen et al., 1996a; Lolli et
al., 2004). Its N- and C-terminal helices form an additional domain, which the authors
speculate to be strictly required for structural integrity of the protein. These results
are consistent with the observation that the N-terminal helix in Cyclin H is held in
place by highly conserved and at the same time specific interactions with the cyclin
fold that do not allow for much flexibility. In other cyclins that regulate cell cycle
progression the N-terminal helices were seen involved in CDK binding (Card et al.,
2000; Jeffrey et al., 1995). The MAT1 protein was proposed to bind to CDK7 itself
rather the cyclin subunit since MAT1 interacts specifically and directly with CDK7
independently of the presence or absence of Cyclin H (Andersen et al., 1996a; Lolli
et al., 2004).
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3. Aims of this work
To elucidate the enigmatic molecular mechanism of Mediator it is necessary to
answer questions using structural information. When this work was started, detailed
structural information on Mediator had not been available. The reasons for this lie in
the difficulties to obtain homogenous and pure fractions from native Mediator
preparations caused by the modularity and low abundance of Mediator in the cell.
Recombinant overexpression had so far not been successful in amounts suitable for
structural studies since multiple protein-protein interactions in the natural complex do
not allow soluble expression of individual subunits.
One main objective of this work was to define an interaction map and stable
subcomplexes within the Mediator head module and to establish a technique that
allowed high expression levels of recombinant subcomplexes. These subcomplexes
can be used for biochemical assays, establishing function towards RNA Pol II, e.g.
determining the RNA Pol II interacting subunits, and can be used for structural
studies with and without RNA Pol II using crystallography. As a short-term goal this
approach can lead to high-resolution structural information of subcomplexes and
subunits within Mediator. In the future, these structures can be located in lower
resolution maps of Mediator becoming available with and without Pol II through
crystallographic and EM techniques. A recombinant core Mediator produced by
overexpression could in turn lead to higher resolutions in structural studies since it
allows absolute homogeneity and can be used for biochemical studies to shed light
on its mechanism in activating RNA Pol II.
The second main objective of this work was to obtain structural information on
the Mediator CDK8/Cyclin C pair. The CDK8/Cyclin C module of Mediator comprises
a kinase activity and is involved in transcriptional regulation. At the time this work
was started the only structural information on CDK/cyclin pairs involved in
transcription was limited to the crystal structure of Cyclin H (Andersen et al., 1996a;
Lolli et al., 2004). It had revealed differences in fold when compared to other cyclins
active in the cell cycle. Detailed structural information on the CDK8/Cyclin C
heterodimer would provide further understanding of such differences. With the
structure of Cyclin C the importance of this cyclin in complex formation and substrate
specificity can be understood. Three dimensional (3D) modeling techniques have the
potential to give first understanding on the specific features of the Mediator kinase
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and allow for speculations on its phosphorylation independent activation as well as
specific and non-specific recognition of CDK and cyclin.
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Materials and Methods
1. Bacterial strains and insect cells
Bacterial strains and insect cell lines used in this work are listed in table 3 and
4 respectively.
Table 3 – bacterial strains
Strain Genotype or description
Source or
reference
Escherichia coli
DH5"
F’ %80dlacZ!M15 !(lacZYA-argF)U169 deoR recA1
endA1 hsdR17(rK
- mK
+) phoA supE44 &- thi-1 gyrA96
relA1
(Woodcock et
al., 1989)
XL-1 blue strain
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac[F’
proAB laclqZ!M15Tn10(Tetr)]
Stratagene
BL21-CodonPlus
(DE3)-RIL
B F- ompT hsdS(rB
- mB
-) dcm+ Tetr gal _(DE3) endA Hte
[argU ileY leuW Camr]
Stratagene
DH10-Bac™
F- mcrA !(mrr-hsdRMS-mcrBC) _80lacZ!M15
!lacX74 recA1 endA1 araD139 !(ara,
leu)7697 galU galK rpsL
nupG/bMON14272/pMON7124
Invitrogen
BL21-(DE3) Stratagene
B834 E. coli (DE3) (hsd metB)
(Budisa et al.,
1995)
Table 4 – insect cells
Cell line Description Source or reference
Spodoptera frugiperda
SF9
Cell line from S. frugiperda gonad
cells
Novagen
2. Plasmids and genomic DNA
Plasmids constructed and used for this work are listed in table 5. Genomic
DNA from S. cerevisae and cDNA from S. pombe was used as template for PCR.
Names refer to S. cerevisiae genes unless marked by Sp (S. pombe). His6 - tags were
always introduced on the C-terminal end.
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Table 5 – plasmids
No Name Vector ABR Insert
Restriction
sites
Affinity tag Remarks
1 Srb4 (MED17) pGex-3x amp MED17 BamHI N-term GST
2
Srb4-F2
(MED17-F2)
pGex-3x amp MED17241-687 BamHI N-term GST
3 Srb4 (MED17) pET21b amp MED17 NheI/NotI none
Stop codon 5’
from His6
4
Srb4!C
(MED17!C)
pET21b amp MED171-630 NheI/NotI His6
5
Srb4!N
(MED17!N)
pET21b amp MED1797-687 NheI/NotI His6
6
Srb4-!C!N
(MED17!C!N)
pET21b amp MED1797-630 NheI/NotI His6
7
Srb4-F1
(MED17-F1)
pET21b amp MED171-240 NheI/NotI His6
8
Srb4-D2
(MED17-D2)
pET21b amp MED171-351 NheI/NotI His6
9
Srb4-D2!N
(MED17-
D2!N)
pET21b amp MED1797-351 NheI/NotI His6
10 Srb4-F2-His pET21b amp MED17241-687 NdeI/NotI none
Stop codon
before C-term
His6
11
Srb4-F2!C
(MED17-F2!C)
pET21b amp MED17241-630 NdeI/NotI His6
12 Rox3-Srb7 pET21b amp
MED19
MED21
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
13 Srb2-Srb7 pET21b amp
MED20
MED21
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
14 Med11-Srb7 pET21b amp
MED11
MED21
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
15 Med8-Srb7 pET21b amp
MED8
MED21
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
16
Med7-
MED17-F2
pET24d kan
MED7GSTtev
MED17-F2241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
17 Rox3-Srb4-F2 pET21b amp
MED19
MED17241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
18 Srb2-Srb4-F2 pET21b amp
MED20
MED17241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
19
Med11-Srb4-
F2
pET21b amp
MED11
MED17241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
20 Med8-Srb4-F2 pET21b amp
MED8
MED17241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
21 Srb6-Srb4-F2 pET21b amp
MED22
MED17241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
22 Srb6-Srb4-F2 pET21b amp
MED22
MED17241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
23
Med6!C-
Srb4-F2
pET21b amp
MED61-214
MED17241-687
NheI/EcoRI
NdeI/ NotI
-
His6
Bicistron I
24
Srb4-F1!N
(MED17-F1!N)
pET21b amp MED1797-240 NheI/NotI His6
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31 Srb10-Srb11Sp pET21b amp
CDK8 Sp
CycCSp
NheI/EcoRI
NcoI/ NotI
-
His6
Bicistron II
32 Srb10Sp pET21b amp CDK8Sp NheI/NotI His6
33 Srb11Sp pET28d kan CycC Sp NcoI/NotI His6
34 Srb10Sp-Bac pFastBac1 amp CDK8 Sp BSSHI/ EcoRI His6
Invitrogen,
His Tag
included in
primer
35 Srb2-Srb5 pET21b amp
MED20
MED18
NheI/EcoRI
NcoI/NotI
-
His6
Bicistron II
36 Srb11Sp-1 pET28d kan CycCSp 5-228 NcoI/NotI none
37 Srb11Sp-2 pET28d kan CycCSp 30-228 NcoI/NotI none
38 Srb11Sp-3 pET28d kan CycCSp 5-228 NcoI/NotI His6
39 Srb11Sp-4 pET28d kan CycCSp 30-228 NcoI/NotI His6
40 Srb11Sp-Meth1 pET28d kan CycCSp L60M NcoI/NotI His6
41 Srb11Sp-Meth2 pET28d kan CycCSp I125M NcoI/NotI His6
42 Srb2-Srb5 pET24b kan
MED20
MED18
NheI/EcoRI
NcoI/NotI
-
His6
Bicistron II
43
Srb11-3Sp-
Meth1
pET28d kan CycCSp 5-228 L60M NcoI/NotI His6
44
Srb11-3Sp-
Meth2
pET28d kan CycCSp 5-228 I125M NcoI/NotI His6
45
Srb11-3Sp-
Meth3
pET28d kan CycCSp 5-228 L186M NcoI/NotI His6
46
Srb11-3Sp-
Meth1,3
pET28d kan
CycCSp 5-228
L60M, L186M
NcoI/NotI
His6
47
Srb11-3Sp-
Meth1,2,3
pET28d kan
CycCSp 5-228
L60M, I125M, L186M
NcoI/NotI
His6
48
Srb2Sp-Srb2-
Srb5
pET24b kan
MED20Sp
MED20
MED18
KpnI/SacI
NheI/EcoRI
NcoI/NotI
-
-
His6
Tricistron II
Two SacI sites
49
Srb2Sp-Srb5-
!C/N
pET24b kan
MED20Sp
-
MED1856-285
KpnI/SacI
-
BamHI/NotI
-
-
His6
Bicistron IV
50
Srb2Sp-Srb2-
Srb5!C/N
pET24b kan
MED20Sp
MED20
MED18.56-285
KpnI/SacI
NheI/EcoRI
BamHI/NotI
-
-
His6
Tricistron III
51
Med8-Srb2-
Srb5!C/N
pET24b kan
MED8
MED20
MED1856-285
NdeI/SacII
NheI/EcoRI
BamHI/NotI
-
-
His6
Tricistron IV
52
Srb2Sp-Srb2-
Srb5!C/N
pET24b kan
MED20Sp
MED20
MED1856-285
KpnI/HindIII
NheI/EcoRI
BamHI/NotI
-
-
His6
Tricistron V
53
Srb2Sp-Srb5Sp-
Srb5!C/N
pET24b kan
MED20Sp
MED18Sp
MED1856-285
KpnI/HindIII
NheI/SacI
BamHI/NotI
-
-
His6
Tricistron VI
54
Med8-Srb2-
Srb5
pET24b kan
MED8
MED20
MED18
NheI/EcoRI
NheI/EcoRI
NcoI/NotI
-
-
His6
Tricistron I
55 Srb2-Srb5!C/N pET24b kan
MED20
MED1856-285
NheI/EcoRI
BamHI/NotI
-
His6
Bicistron III
56 Srb2-Srb5-!N1 pET24b kan
MED20
MED18141-307
NheI/EcoRI
NcoI/NotI
-
His6
Bicistron II
57
Srb4-F2-
MED6!C
pGex-3x amp
MED17241-687
MED61-214
BamHI
NdeI/XmaI
N-term GST
His6
Claudia
Buchen
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58 Srb4-F2-MED6 pGex-3x amp
MED17241-687
MED6
BamHI
NdeI/XmaI
N-term GST
His6
Claudia
Buchen
59 MED6!C pET24d kan MED61-214 NheI/EcoRI His6
60 pfastBacHT A pFastBacHTA amp None MCS
N-term
His6
Invitrogen
61 pfastBacHT B pFastBacHTB amp None MCS
N-term
His6
Invitrogen
62 pFastBacHT C pFastBacHTC amp None MCS
N-term
His6
Invitrogen
63 pFastBac1 pFastBac amp None MCS none Invitrogen
64 pFastBac Dual
pFastBac
Dual
amp None MCS none Invitrogen
65 RY7488 pSK157 amp CDK8 XbaI/BamHI none
R. Young
–baculovirus
transfer vector
66 RY7489 pSK158 amp CDK8 XbaI/BamHI HA “
67 RY7490 pSK159 amp Cyclin C EcoRI/BamHI none “
68 RY7491 psK160 amp Cyclin C EcoRI/BamHI HA “
69 Srb10-Bacmid
Invitrogen
Bacmid from
DH10-Bac™
cells
kan CDK8
Transposon
target sites
His6
For
reamplification
use glycerol
stock
Antibiotic resistences (ABR) are abbreviated as amp (ampicillin) and kan (kanamycin).
3. Media
Growth media that were used for recombinant expression and the according
supplements and antibiotics are listed in tables 6 and 7 respectively.
Table 6 – growth media
LB
(Sambrook and Russel,
2001)
1% tryptone; 0.5% yeast extract; 0.5% NaCl
SOC
(Sambrook and Russel,
2001)
2.0% tryptone, 0.5% yeast extract,
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2,
20 mM MgSO4, 20 mM glucose
SF-900 II (PAA)
Serum free medium for insect cell culture
(recipe see PAA catalogue)
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Table 7 – supplements and antibiotics
Applied to strain or cell line as follows
Supplements and
Antibiotics
stock solution
E. coli
E. coli
DH10Bac
SF9 insect cells
Ampicillin 100 mg/ml in H2O 100 "g/ml -- --
Gentamycin 50 mg/ml in H2O -- 7 "g/ml --
Kanamycin 30 mg/ml in H2O 30 "g/ml 50 "g/ml --
Tetracyclin 12.5 mg/ml -- 10 "g/ml --
Chloramphenicol 50 mg/ml in ethanol 50 "g/ml 20 "g/ml --
IPTG 0.5 M in H2O 0.5 mM 40 "g/ml --
X-Gal
40 mg/ml in dimethyl
formamide
-- 100 "g/ml --
Baculo Gold FCS 100% -- -- 0-10%
Penicillin/
Streptomycin
100x solution
(PAA)
1000 units/ml pen and
1000 "g/ml strep
-- --
50 units/ml pen;
50"g/ml strep
DMSO
(cell culture
grade)
100% -- -- 10%
Baculo FCS Gold was heat inactivated for 30 min at 56° before aliquotation in 50 ml.
4. Buffers and solutions
Tables 8-14 list the buffers and solutions used in this work. Buffers for
individual protein purifications are listed separately along with purification protocols.
Table 8 – buffers and solutions used SDS-PAGE
4x stacking gel buffer 1.5 M Tris; 0.4% (w/v) SDS; pH 8.8
4x separation gel buffer 1.5 M Tris; 0.4% (w/v) SDS; pH 6.8
electrophoresis buffer 1,25 M glycine; 125 mM Tris/Cl; 0.5% (w/v) SDS
2x sample suffer
10% (v/v) glycerol, 50 mM Tris-HCl pH 7.0, 0.1% (w/v)
bromophenol blue, 0.1% (w/v) lauryl sulfate, 1% (w/v)
#-mercaptoethanol, 14% (w/v) 1,4-dithiothreitol
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Table 9 – buffers and solutions for SDS- polyacrylamide gel staining
Coomassie stain solutions
stain solution
50% (v/v) ethanol, 7% (v/v) acetic acid, 0.125% (w/v) Coomassie
Brilliant Blue R-250
Destain solution 5% (v/v) methanol, 7.5% (v/v) acetic acid
Silver stain solutions (Bloom et al., 1987)
fixing solution
50% (v/v) methanol, 12.5% (v/v) acetic acid, 0.0001% (w/v)
formaldehyde (for 50ml: 25 "l of 20% solution)
rinse solution I 50% (v/v) ethanol
rinse solution II 30% (v/v) ethanol
sensitizer 0.02% (w/v) (0.2 mg/ml) sodium thiosulphate
stain solution 0.1% (w/v) silver nitrate, 0.00015% (w/v) formaldehyde
developer
6% (w/v) sodium carbonate, 0.0001% (w/v) formaldehyde,
0.002% (v/v) sensitizer solution (100 "l sensitizer for 50 ml)
stop solution 5% (v/v) acetic acid
Table 10 – buffers and solutions for Western Blot
Transfer buffer
250 mM glycine; 25 mM Tris/HCl; 0,1% (w/v) SDS;
20% (v/v) methanol
Blotting buffer 0.1% (v/v) Tween 20 in PBS
Blocking buffer
0.1% (v/v) Tween 20, 5% (w/v) skimmed milk
powder in PBS
Table 11 – buffers solutions for agarose Gels
6x Sample Buffer
1.5 mg/ml bromophenol blue, 1.5 mg/ml xylene
cyanole, 50% (v/v) glycerol
1x TBE-Electrophoresis-buffer 89 mM Tris, 89 mM boric acid, 2 mM EDTA
Table 12 – buffers for the preparation of competent cells
TFB-1
30 mM KOAc, 50 mM MnCl
2
, 100 mM RbCl,
10 mM CaCl
2
, 15% (v/v) glycerol, pH 5.8
TFB-2
10 mM MOPS (pH 7.0), 10 mM RbCl, 75 mM CaCl
2
,
15% (v/v) glycerol
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Table 13 – sample preparation for Edman sequencing
Blotting buffer 10% (v/v) methanol in ddH2O
Rehydration buffer 200 mM Tris/HCl pH 8.5, 2% (w/v) SDS
Table 14 – GST-CTD pulldown assays
Buffer A
20 mM Hepes pH 7.5, 150 mM NaCl, 10 mM DTT,
1 mM Pefabloc
Buffer B
20 mM Hepes pH 7.5, 1000 mM NaCl, 10 mM DTT,
1 mM Pefabloc
5. Molecular cloning techniques
5.1. Oligonucleotides
PCR primers for cloning genes were constructed in a standard way: after a
9 nt overhang to assure efficiency of cleavage the corresponding restriction sites
were introduced followed by 20 to 25 nt of the sequence of interest on both sites of
the gene. The primers for construction of the bicistron were designed according to
(Lutzmann et al., 2002).
5.2. PCR
Template for PCR was either genomic DNA from S. cerevisiae or cDNA from
S. pombe. DNA was amplified either with ®Herculase (Fermentas) for molecular
cloning or Thermus aquaticus (Taq) DNA polymerase for analytic PCR reactions with
appropriate buffer systems from different commercial and non-commercial sources.
Generally, 50 "l reactions contained 100 "M of each of the four dNTPs, 25 pmol of
each primer, between 1 mM and 2 mM MgCl2 (for Taq only) and approximately 1 ng
of template DNA. For ®Herculase reactions DMSO was added according to the
manufacturers suggestions. Thermocycling program was performed in 30 cycles.
Times and temperatures of denaturation, annealing and elongation were moderately
varied to meet the special requirements of the polymerase and primer-template pairs
used in different amplifications.
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5.3. DNA isolation
E. coli cells from 5 ml of an overnight culture were sedimented by
centrifugation. Plasmid DNA was extracted from the pellet using the Spin
Minipreparation Kit (Qiagen) following the manufacturers instructions.
5.4. Restriction cleavage and dephosphorylation
DNA was cleaved using restriction enzymes and buffers supplied by MBI
Fermentas and New England Biolabs (NEB) with standard protocols. The reaction
was incubated over night when working with PCR fragments in order to facilitate
cleavage close to end. To avoid religation, cleaved vector DNA was treated with calf
intestine alkaline phosphatase (CIAP, Fermentas).
5.5. Ligation
Ligation of DNA fragments was conducted in 20 "l total volumes at 16°C for
two to 16 hours using T4 ligase (MBI Fermentas) and T4 ligase buffer (MBI
Fermentas). In most cases linearized vector was incubated with a large (approx.
tenfold) excess of insert to improve results. Positive clones were verified by
restriction analysis and sequencing.
5.6. Mutagenesis
Generation of point mutations in genes was achieved by the PCR overlap
extension method (Higuchi et al., 1988) where two overlapping PCR products are
produced carrying the desired mutation in the primer. The resulting products serve as
template in a second PCR round.
5.7. Transformation of plasmid DNA
The transformation of plasmid DNA into chemically competent E. coli was
performed with standard heat shock protocols. After thawing a 50 "l aliquot of
competent cells 2 "l of ligation mixture or 1 "l of purified plasmid DNA were added.
Cells were incubated on ice for 30 min, heat shocked at 42°C for 45 sec and
incubated on ice for another two min. Then, 450 "l of LB medium were added to the
cells and the mixture was incubated for 1 h in a 37°C shaker before plating.
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5.8. Preparation of competent cells
200 ml LB media were inoculated with 5 ml of an over-night culture of the
bacterial strain. The cells were grown at 37°C until an OD
600 
of 0.4-0.55 was reached.
After incubation on ice for 10 minutes the cells were centrifuged for 10 minutes at
5,000 rpm and 4°C. All following steps were performed at 4°C. The pellet was
washed with 50 ml TFB 1 buffer and centrifuged again. This pellet was resuspended
in 4 ml TFB 2 buffer, before aliquoting and plunging into liquid nitrogen.
6. Biochemical methods
6.1. Protein expression and purifications
6.1.1. Protein expression in E. coli cells
For the expression of proteins, transformed BL21 CodonPlus (DE3)-RIL cells
were inoculated from a preculture at a 1:100 ratio, grown in LB medium
supplemented with antibiotics at 37°C to an OD600 of 0.5-0.6 and flash cooled
before expression was induced with 0.5 mM IPTG, and carried out over night at
18°C. For selenomethione incorporation, the Cyclin C mutant protein was expressed
in the methionine auxotroph E. coli strain B834 (DE3) (Budisa et al., 1995). Cells
were grown in eight liter LB medium, supplemented with kan (30 mg/l) to and OD of
0.6, harvested by centrifugation (3000 g), and were resuspended in eight liter of
selenomethionine-containing minimal medium (Budisa et al., 1995; Meinhart et al.,
2003). The cell suspension was agitated until growth resumed (2-3 hours) at 18°C,
before expression was induced with 0.5 mM IPTG, and continued over night.
6.1.2. Cell lysis and chromatography
6.1.2.1. Cell lysis and affinity chromatography
Cells from a 2 l expression culture were lysed in a French Pressure Cell in
37 ml lysis buffer. The lysate was cleared by centrifugation (30 min, 16000 rpm,
SS34 rotor) and applied to pre-equilibrated Ni-NTA agarose (1.5ml; Qiagen) or
glutathione-sepharose (1 ml, Amersham) self assembled columns, depending on the
affinity tag. The column was washed with 20 CV of lysis buffer and proteins were
eluted with lysis buffer containing the corresponding competitive reagent. The elution
step was optimized by gradient and varying pH for best yields and purities. For
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column regeneration an elution step with 2 M imidazole or 100 mM glutathione
elution buffer was carried out.
6.1.2.2. Ion exchange chromatography
Mono S HR 5/5, Mono Q HR 5/5, and Mono Q 10/100 GL (all Amersham)
were used for ion exchange chromatography on the Äkta purifier system
(Amersham). Before injection samples were diluted to the gradient starting conditions
by adding low salt buffer and filtered. On the small columns the eluting salt gradient
was usually applied over 15 CV, on the Mono Q 10/100 GL over 7 CV, ranging for
example from 100 mM to 1000 mM NaCl.
6.1.2.3. Gel filtration
Samples generated by ion exchange chromatography were loaded onto
equilibrated Superose6 10/30 HR or Superose12 10/30 HR gel filtration columns
(Amersham). A maximum sample size of 500 "l was achieved by concentration of the
samples. The gelfiltration was continued over at least 1 CV (24 ml) at maximum flow
rates of 0.5 ml/min. To estimate the MW of proteins and complexes, the columns
were calibrated with the Low and the High Molecular Weight Gel Filtration Calibration
Kit (Amersham Pharmacia Biotech), which use proteins in the range between
13.7 kD and 669 kD.
6.1.3. Enrichment of proteins
In order to concentrate protein samples after intermediate and final purification
steps centrifugal filter devices (Amicon® Ultra, Millipore or membra-spin Mini,
membraPure) with 10 kD nominal molecular weight limit were used as described in
the provided protocol.  Concentration was conducted up to the desired volume for
intermediate purification and up to the desired protein concentration in final
concentration steps.
6.1.4. Individual purification protocols
In the following the individual purification protocols for proteins and
multiprotein complexes are listed. Buffers are described as percentage of buffer B/C
in buffer A. For 100x protease inhibitor mix 28.4 "g/ml leupeptin, 137 "g/ml pepstatin
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A, 17 "g/ml methylbenzenesulfonyl chloride and 33 "g/ml benzamidine were
dissolved in ethanol. For elution from affinity columns imidazole was added from a
2M stock pH 8.0 and glutathione was freshly dissolved in water and stock solution
was brought to the corresponding pH by titration.
6.1.4.1. Purification of GST-MED17 (GST-Srb4)
Table 15 – buffers for GST-MED17 purification
Buffer A 50 mM Tris/HCl pH 8.0, 2 mM DTT
Buffer B 1000 mM NaCl, 50 mM Tris/HCl pH 8.0, 2 mM DTT
Elution buffer A, 10 mM glutathione
Cleavage buffer 10% buffer B, 1 mM CaCl2, 20 "l factor Xa
Typically bacterial from 2-8 l expressions were lysed by sonication in 15%
buffer B containing protease inhibitors (Table 15). Cleared lysate was loaded on 1ml
glutathione sepharose column, after washing with lysis buffer followed by buffer A
protein was eluted as three 1 ml fractions. Pooled fractions were subsequently
cleaved with factor Xa. Alternatively protease factor Xa reaction was performed on
the column over night at 4° by applying 1 ml lysis buffer containing 20 U of factor Xa
and 1 mM MgCl2. Gelfiltration was performed with Superose12 and different salt
concentrations (100-300 mM NaCl). After cleavage, protein could be used for limited
proteolysis assays.
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6.1.4.2. Purification of GST-MED17-F2 (GST-Srb4-F2)
Table 16 – buffers for GST-MED17-F2 purification
Buffer A 50 mM Tris/HCl pH 8.0, 10% (v/v) glycerol, 2 mM DTT
Buffer B
1000 mM NaCl, 50 mM Tris/HCl, 10% (v/v) glycerol, 2 mM
DTT
Elution 30% buffer B, 10 mM glutathione
Cleavage buffer Elution buffer, 1 mM CaCl2, 30 "l factor Xa
Mono Q 5/5 HR 20-100% buffer B
Superose12 50% buffer B
Cells from 2 l were lysed in 30% buffer B containing protease inhibitors by
sonication and cleared lysate was applied to a 1ml glutathione sepharose column
(Table 16). After elution in 3 ml, CaCl2 and factor Xa were added to perform cleavage
over night at 4°C. The sample was diluted to meet anion exchange starting
conditions. A gelfiltration was performed at relatively high salt conditions to prevent
aggregation of the protein.
6.1.4.3. Purification of MED17-F1_His6 (Srb4-F1_His6)
Table 17 – buffers for MED17-F1_His6 purification
Buffer A 50 mM Tris-lCl pH 8.0, 10% (v/v) glycerol
Buffer B 1000 mM NaCl, 50 mM Tris-HCl pH 8.0, 10% (v/v) glycerol
Mono Q 5/5 HR 10-100% buffer B, 3 mM DTT
Superose12 30% buffer B, 3mM DTT
Cell pellets from 2-8 l expressions were lysed by sonication in 30 % buffer B
with 10 mM #-mercaptoethanol and 1 mM Pefabloc (Table 17). Column washing was
performed with lysis buffer containing 20 mM imidazole and elution with lysis buffer
containing 300 mM imidazole. A Mono Q 5/5 HR anion exchange run was performed
Materials and Methods
32
followed by a gelfiltration on Superose12. Protein solution was concentrated to
7.5 mg/ml for crystallization set-ups.
6.1.4.4. Purification of MED17-F2_His6-bicistrons
Table 18 – buffers for MED17-F2_His6 purification
Buffer A
50 mM Tris/HCl pH 8.0, 10% (v/v) glycerol
Buffer B 1000 mM NaCl, 50 mM Tris/HCl pH 8.0, 10% (v/v) glycerol
Wash 15% buffer B, 10 mM imidazole, 10 mM #-mercaptoethanol
Elution 15% buffer B, 200 mM imidazole, 10 mM #-mercaptoethanol
Cells from 500 ml liter expression culture were lysed in 15% buffer B
containing 10 mM #-mercaptoethanol and 1 mM Pefabloc (Table 18). Cleared lysate
was applied onto 500 "l Ni-NTA columns. After washing with lysis buffer a washing
step with 10 mM imidazole was performed before elution.
6.1.4.5. Purification of the GST-MED17-F2/MED6!C_His6
Table 19 – buffers for GST-MED17-F2/MED6!C_His6 purification
Lysis buffer
150 mM NaCl, 50 mM Tris, 1 mM EDTA, 10% (v/v) glycerol,
2 mM DTT, 1x protease inhibitors mix
Buffer B
300 mM NaCl, 50 mM Tris, 20% (v/v) glycerol, 2 mM DTT, 1x
protease inhibitors
Elution buffer 10 mM glutathione in buffer B
Ni column buffer
200 mM NaCl, 50 mM Tris, 10% (v/v) glycerol, 10 mM #-
mercaptoethanol
Washes/Elution 0 mM, 10 mM, 20 mM and 300 mM imidazole in Ni column buffer
GSTMED17!N/MED6His6 was purified by sequential Ni-NTA and GST affinity
chromatography (Table 19). After sonication cleared lysate was applied on a
glutathione-sepharose equilibrated with buffer B. After elution sample was diluted to
Ni column buffer. Elution was performed by stepwise increasing the imidazole
concentration, the complex started to elute at 20 mM imidazole.
Materials and Methods
33
6.1.4.6. Purification of MED20/MED18_His6 (Srb2/Srb5_His6) and
MED8/MED20/MED18_His6
Table 20 – buffers for MED20/MED18_His6 and MED8/MED20/MED18_His6 purification
Buffer A
20 mM Tris/HCl pH 8.0, 10% (v/v) glycerol
Buffer B 1000 mM NaCl, 20 mM Tris/HCl pH 8.0, 10% (v/v) glycerol
Mono Q 10/100 GL
10-100% (MED20/MED18_His6) and 10-50% buffer B
(MED8/MED20/MED18_His6), 5 mM DTT
Superose12 15% buffer B, 5 mM DTT
Crystallization
MED20/MED18_His6
2 M NH4SO4, 10 mM DTT
Crystallization
MED20/MED18_His6
2 M NH4SO4, 100 mM NaAcetate pH4.6, 10 mM DTT
Crystallization
MED20/MED18_His6
3.5 M NaFormate, 100 mM NaAcetate pH4.6, 10 mM DTT
Bacterial cells from 0.5-4 l expression were lysed by sonication 15% buffer A
containing 10 mM #-mercaptoethanol and 1 mM Pefabloc and protein complexes
were eluted from a Ni-NTA column with lysis buffer containing 300 mM imidazole
(Table 20). After anion exchange purification and subsequent gelfiltration complexes
were concentrated to 4 and 8 mg/ml for crystallization trials, which in case of the
dimeric MED20/MED18_His6 (Srb2/Srb5_His6) yielded microcrystals complex at the
higher concentration.
The substoichiometrically present trimeric complex can be separated from the
excess of dimeric complex by a very shallow gradient in the anion exchange protocol
and as a separate peak eluting from the gelfiltration.
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6.1.4.7. Purification of the GST-MED17-F2/MED6!C
MED8/MED20/MED18-His6 coexpression
Table 21 – buffers for GST-MED17-F2/MED6!C MED8/MED20/MED18-His6 purification
Buffer A 20 mM Hepes pH 7.5, 5 mM DTT
Buffer B 1000 mM NaCl, 20 mM Hepes pH 7.5, 5 mM DTT
Elution buffer
150 mM NaCl, 20 mM Tris/HCl pH 8.0, 10% (v/v) glycerol, 5 mM
DTT, 50 mM glutathione pH8.0
Mono Q HR 5/5
100-1000 mM NaCl, 20 mM Tris/HCl pH8.0, 10% (v/v) glycerol,
5 mM DTT
Superose12
150 mM NaCl, 20 mM NaCl Tris/HCL pH8.0, 10% (v/v) glycerol,
5 mM DTT
Lysis by sonication of bacterial cells from a 4 l coexpression culture was
conducted in 15% buffer B containing protease inhibitors. Elution from 1 ml
glutathione sepharose was performed with a higher pH Tris buffer to increase elution
efficiency (Table 21). After anion exchange and gelfiltration chromatography,
samples were analyzed by SDS-PAGE and resulting band cleaved and verified by
mass spectrometry.
6.1.4.8. Purification of CDK8_His6
Table 22 – buffers for CDK8_His6 purification
Buffer A
137mM NaCl; 2,7mM KCl; 4,3 mM Na2HPO4•7H2O;
1,4mMKH2PO4; pH 7.4, 1x protease inhibitor mix, 1mM NaF, 0.4
mM Na3VO4, 3 mM DTT
Buffer B like buffer A with 1000 mM NaCl
Buffer C like buffer A with 500 mM imidazole pH 7.4
Sf9 cells from 100-500 ml infected cultures were harvested by centrifugation
(10 min, 300 g, 4°C) resuspended in buffer A, and lysed by sonication for 40 sec
(Table 22). The lysate was cleared by 1h at 100.000 g in a swing out bucket rotor
(4°C) and the cleared lysate was loaded onto a Ni HiTrap column, which was then
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connected to the Äkta purifier system in order to perform two subsequent gradients:
0-100% buffer B and 0-100% buffer C. CDK8_His6 is eluted during the imidazole
gradient. For best results it is advisable to run a slow imidazole elution gradient. A
Mono S cation exchange was performed with 0-100% buffer B.
6.1.4.9. Purification of Cyclin C
Table 23 – buffers for Cyclin C purification
Buffer A 20 mM Tris/HCl pH 8.0, 10% (v/v) glycerol
Buffer B 1000 mM NaCl, 20 mM Tris/HCl pH 8.0, 10% (v/v) glycerol
Mono Q 10-60% buffer B, 5 mM DTT
Superose (6 or 12) 10% buffer B, 5 mM DTT
Crystallization
200 mM magnesium formate, 10 mM DTT
Crystallization
1250 mM NaAcetate, 100 mM imidazole pH 6.0, 7.5% PEG 400,
10 mM DTT
Cells from 2 l expression culture were lysed in 30% buffer B containing 10 mM
#-mercaptoethanol and 1 mM Pefabloc (Roth). Cleared lysate was applied to 1.5 ml
Ni-NTA resin (Table 23). After the elution profile was determined with an imidazole
gradient in the lysis buffer, washing routinely included 2 steps with 2ml 10 mM and 2
steps with 2ml 70 mM imidazole in the lysis buffer. Elution fractions were diluted with
buffer A containing 10 mM #-mercaptoethanol and subjected to Mono Q 5/5 HR
ranging from 10% buffer B to 60% buffer B containing 5 mM DTT over 10 CV,
followed by concentration to 1000 "l total volume and two separate gelfiltration steps
on a Superose column with 10% buffer B containing 5 mM DTT. For crystallization
Cyclin C was concentrated to approx. 4 mg/ml.
6.2. Limited Proteolysis
 For chymotrypsin and trypsin treatment 0.25 "g of protease per gel sample
was added to the total protein mixture in the reaction buffer. At each time point a
sample of 50 "l was taken out and pipetted into a prepared tube with 10 "l 6x sample
buffer to be boiled immediately. For subtilisin or proteinase K treatment protein
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samples where pipetted into separate tubes and 1 "l of protease mixture at various
concentration (430 ng/"l, 43 ng/"l, 4.3 ng/"l and 0.43 ng/"l for proteinase K and
1 "g/"l, 100 ng/"l, 10 ng/"l and 1 ng/"l for subtilisin, empirical values) was added.
The mixture was incubated for 1 h on ice before adding 10 "l 6x sample buffer and
boiling. Ideally the protein concentration was adjusted to yield around 50 "g of
protein per sample. In case these amounts were not at hand, silver staining of gels
was conducted to determine a time/concentration point where intermediary products
are visible and perform the experiment in a second round only with the determined
incubation time. In this case the samples were precipitated with –20 °C acetone and
pellets resuspended in 1x sample buffer before SDS-PAGE. Bands visible in a
Coomassie-stained gel were either reproduced and blotted onto PVDF membrane to
be cleaved or cleaved directly and transferred to PVDF membrane by the passive
transfer protocol before Edman sequencing with Procise® Protein Sequencing
System (Applied Biosystems).
6.3. Determination of protein-protein interactions
6.3.1. GST Sepharose® pull-down assay
For GST pull-down assays 1.5 ml cleared lysates from GST-CTD expression
and GST alone control expression were incubated for 4 h on a turning wheel at 4°C
with 30 "l of equilibrated GST Sepharose® beads (Amersham). Four washing steps,
consisting in 1ml washes twice with lysis buffer, once lysis buffer with 1000 mM NaCl
and once with lysis buffer followed by a 1 min centrifugation at 300g, 4°C were
performed. After washing the bound protein was estimated with a Bradford assay and
the amount of resin solution was normalized to equal concentrations of GST. A resin
alone control was prepared for the second incubation step. In this step 60 "g of
purified Cyclin C was added to the beads in 1.5 ml volume of lysis buffer containing
biotin (300 "g) and varying amounts of NP40. The incubation was performed for four
hours on the turning wheel at 4°C. Three washes were performed with the
corresponding buffer conditions without Cyclin C before 40 "l of 1x sample buffer
was added, samples where boiled and analyzed by SDS-Page and Western-blotting.
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6.3.2. Microcalorimetry
Temperature changes upon consecutive injections of 15 "l peptide solution
(50 "m) into 1.4 ml of a 5 mM Cyclin C solution (in 100 mM NaCl, 20 mM Tris pH8.0,
10% glycerol, 5 mM #-mercaptoethanol) measured in a isothermal microcalorimeter
(VP-ITC, MicroCal) For accuracy protein and peptide concentrations were calculated
from the absorption at 280 nm. As a control temperature changes upon injection of
buffer only into the Cyclin C solution was measured.
7. SF9 insect cell culture and recombinant baculovirus expression
techniques
7.1. Growth conditions for SF9 cells
Insect cells were grown in SF900 II medium without antibiotics at 27°C when
not infected and at 28°C when infected with virus. Doubling time of healthy cultures
was usually approx. 24h and was determined with a Neubauer improved counting
chamber (Peske). Unless for subsequent freezing or in case of slower doubling times
or apparent system malfunctions cells were grown without FCS, for bigger
expression penicillin/streptomycin was added. Cells were split 1:3 into fresh flasks
approx every 2-3 days when culture plate or flask became 100% confluent.
7.2. Freezing and thawing of insect cells
For long term storage and strain establishment, insect cells were harvested at
80% confluence in mid-log phase, centrifuged at 300 g for 10min and resuspended in
medium containing 10% DMSO and aliquoted. Subsequently cells were slowly
cooled down for 1 h at –20°C before transferring them to –80°C and finally into liquid
nitrogen. For thawing, a 1 ml liquid nitrogen stock was quickly submerged in a 37°C
water bath until it was completely thawed (1-2 min) avoiding shaking. The culture
was quickly pipetted into tissue culture 25 ml flask with 5 ml preheated medium using
a sterile plastic Pasteur pipette to avoid shearing forces that would occur with pipette
tips with smaller outlets. Cells were allowed to settle during 1 h at room temperature
with the colonizable surface of the flask being reduced by creating an inclined plane.
After 1 h medium was carefully removed and fresh preheated medium was provided,
cells were transferred into the 27°C incubator. Subsequently medium was exchanged
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several times on the same day and then once a day until the plate was confluent
again and split with normal rates.
7.3. Transposon mutagenesis and blue/white selection
The pFastBac1-CDK8 plasmid was transformed into DH10-BacTM cells.
Instead of directly plating the cells after heat shock recovery (in 1 ml SOC medium),
10 ml of SOC medium supplemented with kan, tet and gen were added and cells
were grown for 96 h under vigorous shaking (230 rpm) at 37°C before plating them at
three different concentrations (1:1, 1:10 and 1:100) onto fresh Blue/White selection
plates containing the antibiotics plus IPTG and X-Gal. Plates where incubated over
night at 37 °C. Suitable white colonies were picked and replated on selection plates
for a color control. A glycerol stock was prepared (addition of 20% sterile glycerol in
1 ml total volume, storage at -80°C) and the DNA was isolated as described above
with the user-adapted protocol for MidiPrep with the Qiagen Kit. Success of
mutagenesis was controlled by PCR using combinations of M13 primers, CDK8
specific primers, and combinations of both.
7.4. Isolation of Bacmid DNA
For the isolation of Bacmid DNA, a 100 ml culture with selective LB medium
was inoculated with 0.5 ml from a 5 ml overnight starter culture of recombinant
DH10 Bac cells and grown for 14 h under vigorous shaking (250 rpm). DNA was
isolated with the DNA MidiPrep Kit according to a user adapted protocol where the
QF elution buffer was preheated to 65°C and elution was performed in five 1ml steps
instead of one 5ml step. This leads to a higher yields of high molecular weight DNA,
the division in 5 steps prevents cooling of the buffer. Bacmid DNA was resuspended
in 100 "l TE buffer and had a concentration of 580 "g/ml.
7.5. Transfection of SF9 cells with Bacmid DNA
15 "l of Bacmid DNA at 581 ng/"l and 18 "l of Lipofectin (Invitrogen) were
each mixed thoroughly with 250 "l of serum free medium without antibiotics in sterile
tubes made of polystyrene (Falcon). Usage of a different material greatly reduces
transfection efficiency as DNA-lipid complexes stick to the reaction tube when this is
made for example of polyethylene. The two solutions were combined and incubated
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at room temperature for 15-45 min. For transfection 2 ml of medium was added to the
transfection mix, an 80% confluent mid-log phase 5 ml insect culture was washed
once with medium and overlaid with the mix. Cells were incubated at 28°C for 5
hours before the transfection mix was aspirated off and overlaid with 5 ml medium
containing antibiotics. Cells were incubated for 5 days and supernatant was
harvested by centrifugation (10 min, 300g, 4°C).
7.6. Harvesting of initial virus stocks and virus reamplification
The 5 ml first generation virus stock was split in two and two 80% confluent
mid-log phase 5 ml insect cell cultures were reinfected overlaying the culture with 4
ml fresh medium and adding 2.5 ml virus stock to each flask. Cells were incubated
until lysis occurred (5 days) and supernatants were harvested by centrifugation. In a
third and fourth step culture sizes were increased by diluting the virus 1:4 and 1:10
respectively and infection were carried out for 48 h. Supernatants from subsequent
expression tests (48-72 h) were pooled and used as the working virus stock. An
optimal infection ratio of 1:7 where 90% of the cells had detached 24 h postinfection
was determined for this stock. Supernatants of subsequent infections were pooled for
a new stock. Virus stocks were stored at 4°, where they are stable for a few weeks.
7.7. Expression of CDK8
Expression was carried out applying fresh medium mixed at a 1:7 ratio with
infectious supernatant onto an 80% confluent plate that had been split the previous
day. The optimal infection time was determined and further expression were carried
out for 24 h before cells were harvested by centrifugation at 4°C and resuspended in
lysis buffer. Supernatant was removed and reused as described.
8. Electrophoretic methods
8.1. Electrophoretic separation of DNA
DNA was separated in horizontal TBE 1% agarose gels; the ethidium bromide
concentration in the gels was 0.7 "g/ml. Samples were mixed with 1/10 vol. of
sample buffer. For visualization of DNA the gel was placed on a UV-screen (Eagle
Eye', Stratagene)
Materials and Methods
40
8.2. Protein separation by SDS-PAGE
For proteins samples glycine-SDS-PAGE with 10%-17% acrylamide gels
(Laemmli, 1970) was performed. Gels were then either subjected to protein transfer
for Western-blot or directly stained with Coomassie solution. Silver staining was
performed (1h fixing, 2x10min washing, 1min sensitizing, 3x30sec H2O wash, 20sec
staining, 2x 30sec H2O wash, development, reaction stop) when very low amounts of
proteins had to be visualized.
9. Immunological methods
9.1. Protein transfer and Western blot
After SDS-Page proteins were blotted in a transfer chamber (BioRad Trans-
Blot Cell) for either 1 h at 90 V, 3 h at 60 V or 16 h at 20 V onto PVDF membranes
(Roth), prewet with ethanol. Blotting steps included 1 h blocking of unspecific
interactions and 1 h incubation time for each antibody. Washing steps were carried
out after each antibody incubation for 15 min followed by two times 10 min. Either the
secondary or primary antibody was coupled to HRP (horse-radish-peroxidase) and
detection was performed with the ECL Plus reagents (Amersham Pharmacia Biotech)
following the manufacturers instructions.
9.2. Passive adsorption method for protein transfer
Alternatively proteins can be transferred to PVDF membrane by passive
adsorption. This is particularly useful for Edman sequencing because it avoid
N-terminal end blocking produced by electric transfer. Coomassie stained bands are
directly cut from the gel and dried in a Speed Vac. Dried pieces were swollen in 50 "l
swelling buffer. After addition of 200 "l H20 a 1-5 mm
2 piece of prewet (methanol)
membrane was added. Methanol was added to 10% final concentration after the
solution had began to turn blue. After 1-2 days, membrane was washed by vortexing
five times with 1 ml 10% MeOH for 30 sec.
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10. Crystallization
Crystal setups were performed either manually with the hanging drop vapor
diffusion method or with the crystallization robot  (Hydra Plus 1) as sitting drops in
96-well plates at 20°C. Full-length Cyclin C was crystallized with the hanging drop
method using as reservoir solution 250 mM magnesium formate, 25% glycerol, and
10 mM DTT, reached a maximum size of 70 x 70 x 70 "m, and could be flash-cooled
directly from the hanging drop. The variant comprising residues 5-228 was highly
soluble and could be crystallized using a reservoir solution containing 1.25 M sodium
acetate, 100 mM imidazole pH 6.5, 7.5% PEG 400, and 10 mM DTT with a protein to
crystallization solution ratio of 2:1. Crystals were harvested in the reservoir solution.
The PEG 400 concentration was increased to 25% in six steps using an incubation
time of one hour after each step. Crystals were slowly cooled to 4° in a styrofoam
box, incubated overnight, mounted into nylon loops (Hampton research), and were
plunged into liquid nitrogen for storage.
11. X-Ray analysis
11.1. Data collection
Data were collected at the protein crystallography beam line X06SA at the
Swiss Light Source (SLS), Villigen/Aargau. This was necessary since the crystals
showed a rather low diffraction power. Additionally they were very radiation sensitive.
Therefore a rotation of 0.5° per frame was chosen, which would allow
obtaining good I/sigma (I) values with a low x-ray dose. This strategy was combined
with a beam focused on the detector rather than on the sample. Radiation damage
was observed in a reduction of high angle intensities due to disorder. Since radiation
damage usually continues at a steady state rate, even if exposure ceases (probably
due to effects initiated by free radical), intensity measurements were carried out
rapidly and without interruption. Since the signal-to-noise ratio increases with the
distance, the maximum reasonable crystal to detector distance was chosen for data
collection.
In order to achieve maximum redundancy (total number of reflections
measured/total number of unique reflections) and a high completeness (total number
of intensity measurements/total number of measured unique reflections), the total
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oscillation range of 100° as well as the starting point was determined prior to data
collection with MOSFLM (Powell, 1999).
Multi wavelength anomalous dispersionn (MAD) datasets were recorded from
selenomethionine-containing crystals. In order to exploit the changes in both the
normal scattering (f`H) and the anomalous scattering (f`H) of the anomalous scatterer
(selenium) three datasets with 100° each were measured at wavelengths close to the
absorption band. Peak data at a wavelength of 0.97977 Å were recorded first, then
data at the inflection point at 0.98004Å and remote data at 0.94927 Å.
12. Data processing and structure solution
12.1. Indexing, integration and scaling
Data were processed with DENZO and SCALEPACK (Otwinowski and Minor,
1996), except the native dataset, which was processed with MOSFLM and SCALA
(CCP4, 1994) and data from  peptide soaking experiments, which were processed
with HKL2000 (Otwinowski and Minor, 1996). For the MAD data the error model was
adjusted for the remote data set and applied to the two remaining datasets.
12.2. Phasing
Program SOLVE (Terwilliger, 2002) was used for MAD phasing with the
datasets from selenomethionine containing crystals. Phases were improved with
SHARP (La Fortelle and Bricogne, 1997). The resulting electron density map was
used for positioning a polyalanine model of the cores of the two helical cyclin repeats.
Subsequent phase combination and phase extension to 3.0 Å with amplitudes from
native data allowed building of an atomic model. For cocrystallization and peptide
soaking experiments, phases were obtained by molecular replacement with the
Cyclin C structure using the program PHASER (Storoni et al., 2004) followed by a
rigid body refinement. In order to avoid loss of a weak additional density bulk solvent
correction was disabled in this and all following refinement steps.
12.3. Refinement
Refinement of the structure with CNS (Brunger et al., 1998) consisting of
rounds of application of the routines MINIMIZE and BINDIVIDUAL. Quality of the
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resulting model was analyzed with 2Fo-Fc and Fo-Fc electron density maps.
Stereochemistry was judged with PROCHECK (Laskowski et al., 1993b).
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Results
1. Mapping of subunit domains and subunit-subunit interactions
within the Mediator head module
The Mediator head module, which consists of eight subunits, tightly binds to
RNA Pol II (Davis et al., 2002). Determining a detailed interaction map of stable
subcomplexes within the Mediator head module is the first step to achieve high
expression levels of recombinant subcomplexes. Individually expressed recombinant
Mediator subunits are generally insoluble, explaining the current lack of Mediator
subunit structures. Insolubility apparently results from a loss of structural integrity
when subunits are outside their natural multiprotein context. To overcome this
obstacle and to analyze at the same time subunit interactions within the Mediator
head module, a coexpression strategy was combined with limited proteolysis studies.
Domain mapping through limited proteolysis and bioinformatical tools led to truncated
and more stable variants of the subunits. Subsequently stable variants were
coexpressed and copurified with binding partners. Iterative proteolysis and truncation
of the coexpressed and copurified subunits allows the determination of stable
subcomplexes. This approach may be used to obtain potentially crystallizable
portions of other multiprotein complexes.
1.1. MED17 (Srb4), the integral subunit of the Mediator head module
The MED17 (Srb4) protein binds several subunits within the Mediator head
module (ref). This 75 kD protein is therefore regarded as a scaffold protein in the
head module, making it as much an interesting as difficult target for structural
studies. The Srb4 structure would provide information on the organization and
function of this module. Srb4 is very difficult to express alone.
As a first attempt to obtain MED17 in soluble form overexpressed GST-
MED17 (Srb4) fusion protein was purified in a three-step protocol. It consisted in an
affinity chromatography over glutathione-sepharose, a MonoQ anion exchange
chromatography and a final gelfiltration step over a Superose12 column. The yield of
protein did not exceed 50 "g from a 4 liter culture. From gelfiltration it was clear that
most of the protein was aggregated since it all eluted in the void volume. The
expression protocol for MED17 (Srb4) could still be improved by optimizing time,
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temperature and expression strand. The resulting standard protocol consisted of
expression over night at 18°C with the BL21RIL strand. In order to prevent the
protein from aggregating, experiments were carried out in different buffer and salt
conditions. Despite some improvement, purification would be very limited by low
yields and copurification of the chaperone DnaK (confirmed with Edman sequencing),
a fact underlining the partially misfolded nature of the recombinantly expressed
protein.
Fig. 2 – Overall structure of RNA Pol II-Mediator complex and subunits of the head module.
The Mediator of transcriptional activation binds extensively to RNA Polymerase II as it can be
derived from EM- analysis (left picture, Davis et al., 2002). The head module is thought to be
the major RNA Pol II interacting module. It is not clear where and by which of the eight
subunits this binding occurs, nor has it been proven how they are organized among each
other. A yellow circle lines the subunits essential in S. cerevisiae.
Limited proteolysis revealed two stable domains of MED17 (Srb4), referred to
as F1 and F2 fragment. The complete MED17 (Srb4) fraction from a large-scale
expression was subjected to partial proteolysis using chymotrypsin and trypsin, to
probe for flexible regions that may interfere with solubility and stable domains
suitable for a high yield expression. Two cleaved fragments starting with amino acid
97 and 241 were identified by Edman sequencing (Fig. 3A). This information,
combined with secondary structure prediction, allowed the design of several new
constructs and variants, which were tested for their expression levels and solubility.
The resulting MED17 (Srb4) domain structure, the secondary structure prediction,
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conserved essential regions, as well as important sites determined by other groups
are summarized as a map in figure 3B.
A
B
Fig. 3 – Analysis of MED17 (Srb4) domain structure. (A) Limited proteolysis using
chymotrypsin reveals a cleavage site at amino acid 241 and an estimated site at the C-
terminus. Full-length MED17 (Srb4) and the two intermediary products MED17-F2 (residues
241-687) and MED17-F2!C (residues 241-630) that appear 30`` and 5´ respectively after
addition of protease are marked with a star. (B) Summary of the results on MED17 (Srb4)
domain analysis. Results from previous genetic and biochemical studies are listed along with
results from secondary structure prediction and limited proteolysis. Two constructs designed
according to these results led to soluble protein variants. The other protein variants
displayed, if at all, very low expression levels, indistinguishable from background in affinity
purifications.
Results
47
1.2. Two fragments of MED17 (Srb4) display better expression and
solubility than full-length protein
Most of the variants of MED17 (Srb4) could not be overexpressed (Fig. 3B).
Only the two major products of the proteolysis assay led to soluble variants, MED17-
F1 and MED17-F2. However, MED17-F2 was poorly expressed and difficult to purify.
To prevent aggregation, a protocol using high salt concentrations for the gelfiltration
chromatography had to be established, which led to some improvement. Neither the
GST-fused MED17-F2 nor a version with a C-terminal hexahistidine tag could be
purified in amounts suitable for crystallization. In contrast, the short MED17-F1 with a
C-terminal hexahistidine-tag was in expressed soluble form in reasonable amounts, a
purification protocol was established, and a CD spectrum indicated proper folding
(data not shown). Crystallization screens using standard Hampton Research
conditions did not yield crystals.
1.3. Bicistronic expressions of MED17 (Srb4) with the other Mediator head
module subunits reveals binding to MED6 and MED8
The main obstacles for reconstitution of Mediator head module are poor
expression levels and insolubility of E. coli expressed proteins. The loss of structural
integrity from which individual subunits suffer outside their natural multiprotein
context can be overcome by multicistronic expression strategies. A multicistronic
mRNA contains individual ribosomal binding sites (RBS) for each gene. When the
mRNA is translated the nascent polypeptide chains of partner proteins are
synthesized in close proximity, favoring immediate formation of the stabilizing
complex. Subsequently coexpressed subunits are copurifed.
Thus data obtained from proteolysis and domain mapping can be used in
attempts to improve expression and solubility by coexpression with potential binding
partners. At the same time such copurification can successfully map strong and
specific direct protein-protein interactions, as demonstrated by subsequent structure
solutions of such protein complexes (Baumli et al., 2005). Specific interaction is
indicated by the fact that only one protein carries an affinity tag and the potential
interaction partner can be copurified. The copurification assay is very stringent, since
many different non-specific competitor proteins are present in the E. coli lysate, since
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the stoichiometry of the complexes can be estimated with Coomassie-stained gels,
and since the protein-protein complexes persist over several copurification steps.
1.3.1. Screening with bicistronic vectors reveals binding of MED17 to
MED8
For screening protein-protein interactions in the Mediator head module
bicistronic expression vectors were designed systematically by combining the
MED17-F2 fragment with other subunits of the Mediator head module. Except MED6
and MED8 none of the subunits could be copurified with MED17-F2 (Fig. 4).
As expected for a scaffold protein, offering just a single expression partner did
not fully overcome problems in expression and solubility. No effect could be seen in
combination with MED19 (Rox3), MED20 (Srb2), MED11, and MED22 (Srb6) (not
shown). Apart from not binding at all to MED17 (SRB4), some of them might also
bind the conserved region in the MED17-F1 fragment (Fig. 3B). Determination of a
recombinantly expressed and soluble subcomplex out of this dense network of
interactions will need further combinatorial trials to define the minimally required
interactions.
In this screen MED8 was determined for the first time an interaction partner of
the MED17-F2 fragment. MED17-F2 yields are much higher and an additional
stoichiometric binding partner is detected in the Coomassie stained gel when
compared with the other co-purification assays (Fig. 4A). The protein band was
excised from the gel and identified by mass spectrometry as MED8. MED8 is thus
stoichiometrically copurified in an affinity purification targeting only MED17 (SRB4).
Copurification was confirmed at a later stage in large-scale expressions, but the
tendency of MED17-F2 and maybe also MED8 to aggregate prevented high yield
purification results.
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Fig. 4 – Screen of bicistronic expression within the Mediator head module. (A) Affinity
purification of coexpression tests of MED17-F2-His6 with MED8, MED11, MED19, MED20.
Bands that could be identified (by Western Blot, Edman sequencing, or mass spectrometry)
are marked with an arrow. (B) Summary on results of bicistronic expression with MED17-F2-
His6. Expression and solubility in the individual expression tests are indicated.
1.3.2. MED6 bridges the two Mediator core modules
It was shown (Baumli et al., 2005) that the MED7/MED21 heterodimer binds
directly to MED6, which shows 34% sequence homology between yeast and human
(Fig. 5A). MED6 is an integral part of the head module (Lee and Kim, 1998),
suggesting that MED6 bridges between these two modules. To test if MED6 binds
directly to MED17 (SRB4), the architectural subunit of the head module (Koh et al.,
1998), MED6 was tagged with a C-terminal hexahistidine tag (His6), fused MED17
(SRB4) to a N-terminal GST tag (GST), and the two subunits were coexpressed from
a bicistronic vector. In two subsequent affinity chromatography steps, using a Ni-NTA
and a glutathione column, the complex was copurified (Fig. 5A). Successful
purification of the complex was independent of the order of the affinity columns (Fig.
5B). The weakly conserved N-terminal part of MED17 (SRB4), MED17-F1, and the
non-conserved C-terminal part of MED6, are not required for binding since truncated
variants of MED17 (MED17-F2, residues 241-688) and MED6 (residues 1-214) were
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sufficient for the interaction. These results are consistent with a functional interaction
between MED17 (SRB4) and MED6 observed previously (Lee and Kim, 1998). The
results are further consistent with a very recent study of Mediator subunit interactions
by yeast two-hybrid analysis (Guglielmi et al., 2004). In conclusion, MED6 physically
bridges between the two Mediator core modules, interacting with MED17 (SRB4) in
the head module and with the MED7/MED21 heterodimer in the middle module.
Fig. 5 - Copurification of MED6 with MED17 (Srb4). (A) copurification of MED6-His6 with
GST-MED17!N. A schematic presentation of the purification procedure is shown above the
Coomassie stained gel. (B) Western blot of the GST-MED17!N/MED6-His6 purification.
Binding of MED6 to MED17 is not due to the presence of the GST tag since a purification
using GST only does not yield MED6 (fourth lane).
1.4. A trimeric subcomplex MED20/MED18/MED8 in the Mediator head
module
1.4.1. Preparation of soluble MED20/MED18 (Srb2/Srb5) - heterodimer
The MED20 (Srb2) and MED18 (Srb5) proteins are non-essential in yeast but
highly conserved subunits of the Mediator head module. In contrast to expression of
MED20 (Srb2) in a bicistronic vector with MED17 (Srb4) (Fig. 4), which results in
insoluble protein, offering MED18 (Srb5) as a binding partner yields high amounts of
soluble protein, demonstrating the effectiveness of this method as soon as the right
interaction partners are brought together (Fig. 6A, upper construct). High yields
(10 mg pure protein from 500 ml of E. coli culture) of the complex were copurified
stoichiometrically over a Ni-NTA affinity column using a C-terminal His tag only on
MED18 (Srb5), a MonoQ anion exchange column and a Superose gelfiltration
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column (Fig. 6B, left panel). The complex was stable in solution at 4°C for several
weeks.
Fig. 6 – Stable subcomplexes within the Mediator head module: MED20/MED18 form a
stable dimmer that interacts with MED8. (A) multicistronic expression constructs. (B)
purification and limited proteolysis of the dimeric MED20/MED18 complex and (C) the
trimeric MED20/MED18/MED8 complex. The left panel of (A) and (B) shows the complex as
it was purified in a three-step protocol. Tryptic digestion and proteinase K digestion were
performed with both complexes. Stable intermediary products that were subsequently
analyzed by N-terminal sequencing (see Fig. 8A and text) are marked with a star.
1.4.2. Crystallization of MED20/MED18 (Srb2/Srb5) heterodimer
Crystallization screens were performed at two concentration of the
MED20/MED18 complex using standard Hampton Research screens. Microcrystals
grew in two conditions (2 M NH4SO4, 10 mM DTT and 2 M NH4SO4, 100 mM
NaAcetate pH4.6, 10 mM DTT), but fine screens did not yield any improvement (Fig.
7). Additional screens performed at higher salt concentrations yielded additional
microcrystals, of which those grown in 100 mM NaAcetate pH4.6, 3.5 M Na formate,
10 mM DTT looked worth further refinement. The majority of the drops remained
clear even at very high salt concentration and a protein concentration of 40 mg/ml.
Results
52
Fig. 7 – The MED20/MED18 heterodimer forms microcrystals at 8mg/ml in 2 M NH4SO4,
100 mM NaAcetate pH4.6, 10 mM DTT. Hanging drop (1.5 "l: 1.5 "l) crystallization was
performed with the dimeric complex at two protein concentrations. A picture was taken from
a drop containing microcrystals of around 5 "m lengths.
1.4.3. MED8 binds to the MED20/MED18 (Srb2/Srb5) heterodimer
In a first attempt to construct a tricistonic vector the med8  gene was
introduced with an additional RBS into the bicistronic vector containing the MED20
(Srb2) and MED18 (Srb5) genes (Fig. 6A, lower construct). After affinity
chromatography and anion exchange chromatography, MED8 elutes with
MED20/MED18 (Srb2/Srb5) in a stoichiometric trimeric complex from the gelfiltration
column (Fig. 6C, left panel), proving the interaction. A big excess of the dimeric
complex elutes from the gelfiltration column before the trimeric complex (not shown).
This indicates a low stability of the MED8 protein. No crystals could be obtained from
the trimeric complex in standard screens. In conclusion MED8 forms a complex with
MED20/MED18 (Srb2/Srb5).
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1.4.4. Limited proteolysis reveals potential variants of MED18 (Srb5)
and confirms the high sensitivity and instability of the MED8 protein
In order to screen for stable domains in the dimeric as well as in the trimeric
complex, both complexes were subjected to limited proteolysis experiments with
subtilisin (Fig. 6B,C right panels) and trypsin (not shown).
Fig. 8 – MED18 contains several protease sensitive sites. (A) Results from Edman
sequencing of protease cleavage products are highlighted in the MED18 amino acid
sequence. A number identifies their sequence position. An estimated C-terminal cleavage
site is indicated by a triangle. The predicted secondary structure is outlined above the
sequence with helices represented as rectangles and #-strands as arrows. (B) New
bicistronic constructs that were designed based on limited proteolysis results led to insoluble
proteins.
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Consistent with its behavior in the purification of the stoichiometric trimeric
complex, MED8 is a very unstable subunit in this subcomplex context. It is degraded
at very low protease concentration and needs further binding partners for protection,
possibly MED17 (Srb4).
Three N-terminal cleavage sites on MED18, amino acids position 56, 123, and
141, were identified with limited proteolysis and subsequent N- terminal sequencing
of the resulting stable fragments. A C-terminal cleavage site, amino acid position
285, was estimated combining the size of the stable fragments with secondary
structure position (Fig. 8A). Cleavage results for MED18 (Srb5) matched well with a
secondary structure prediction (Fig. 8A). Variants of MED18 were subcloned in
bicistronic vectors with MED20 (Srb2) and tested for behavior. All of them turned out
to be insoluble (Fig. 8B), indicating either that cleavage sites consist in internal loop
regions or binding with the partner molecule MED20 (Srb2) was impaired by
truncation.
1.5. Design of a new tricistronic vector
The first generation of tricistronic vector was not very useful for further
screening of interactions in the Mediator head module or other multiprotein
complexes. The fasted way to test the tricistronic expression principle had involved
duplication of a multiple cloning site rendering this construct non suitable for further
gene exchanges. In order to easily exchange genes in this arrangement a vector was
needed that allows easy switching between bi- and tricistronic expression and offers
a variety of cloning sites for each of the three genes to provide higher flexibility. As in
the previous bi- and tricistronic systems the last genes would be fused to a C-
terminal His6-tag. The complete cassette of the second and the third gene can be
excised with NdeI /NotI and thus be introduced into a new vector in order to give rise
to a bicistronic construct and vice versa. Since the restriction sites are compatible
with the GST-fusion vectors constructed in the lab, a switch into a system with a
different tag would also be easy to realize. Figure 9 provides a generalized map of
the new vector. It was constructed in several variants with alternative restriction sites.
Detailed information on sequences, restriction sites, and resistance cassettes is
provided in Materials and Methods (table 5, tricistron II) and as supplementary
material.
Results
55
Fig. 9 – Outline of the vector construct for tricistronic expression. The vector, based on a
pET24b vector (Novagen), was constructed by ligating PCR products that contained
additional restriction sites, ribosomal binding sites and genes of interest. An alternative
variant contains an NcoI site instead of the BamHI site. By cleaving with NheI and NotI a
bicistronic construct can be transferred directly from or to the bicistronic vectors.
1.6. MED18 binds to MED8
The first genes cloned into the new tricistronic vector were the S. pombe
med20/med18/med8 genes. The alignment of these and other Mediator proteins over
different species revealed a high number of potential long loops in the S. cerevisiae
proteins. This fact made it worth switching to the proteins from S. pombe, where
secondary structure prediction points to fewer unordered regions. As a consequence
of experiences with the stability of MED8, it was chosen as the tagged protein. This
allows for selection of homogeneous trimeric complex. The cloned med20 gene
corresponds to the one suggested by the literature (Boube et al., 2002) even though
it is not clear whether a MED20 (Srb2) homolog exists in S. pombe, since sequence
homologies are very low. When the tricistronic med20/med18/med8-His6 construct is
expressed in E. coli, MED20 does not copurify with the complex posing the question
whether the used gene really codes for the correct MED20 protein and whether a
MED20 homolog even exists in S. pombe. Further investigations will have to address
the question of a different behavior and possibly different interaction pattern of
MED20 in S. pombe.
As an indirect result of the missing MED20 it becomes clear that in S. pombe
MED18 directly interacts with MED8. MED18 is stoichiometrically copurified with
MED8 after an affinity purification step directed against MED8-His6. This dimeric
complex crystallizes (L. Lariviere, unpublished data).
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1.7. Coexpression of the dimeric MED6/MED17-F2 (Srb4-F2) and the
trimeric MED20/MED18/MED8 (Srb2/Srb5/MED8) complex results in a
pentameric head module subcomplex
The head module scaffold protein MED 17 (Srb4) binds MED6 as well as
MED8. MED8 in turn was shown to bind the MED20/MED18 (Srb2/Srb5)
heterodimer. To reconstitute a subcomplex consisting of MED6, MED17, MED8,
Med20 and MED18 from recombinant proteins, the bicistronic GST-MED17-Med6-
His6 construct was coexpressed with the tricistonic MED8-MED20-MED18-His6
construct. A copurification via the only GST-tag in this five subunits and subsequent
copurification over anion exchange and gelfiltration proves the predicted binding
pattern (Fig. 10). The presence of all subunits in the complex was verified by mass
spectrometry. Nevertheless, a high percentage of the purified protein elutes from a
superose column in the void volume, and is thus aggregated. The individual subunits
were not stoichiometrically present, which could be the result of different stabilities or
impaired binding because of the GST-tag. Interestingly MED17-F2 and MED18
appear rather stoichiometric.
Fig. 10 – A hetero-pentameric subcomplex of the Mediator head module is purified after
coexpression of bi- and tricistronic constructs. The GST-MED17-F2/MED6!C construct was
coexpressed with the MED8/MED20/MED18-His construct and purified over a glutathione
sepharose, an anion exchange and a size exclusion column. Resulting bands were cut from
a Coomassie stained gel and analyzed by mass spectrometry. All the originally expressed
subunits or their degradation product were purified using just a single affinity tag on MED17
(SRB4), consistent with the predicted interaction map.
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1.8. Overview on discovered contacts in the Mediator head module
Figure 11 represents an interaction map of the Mediator head module as it
was derived from this work. These data are consistent with interaction studies using
yeast two hybrid screens and pulldown assays (Guglielmi et al., 2004; Ito et al., 2001;
Kang et al., 2001; Koh et al., 1998; Lee et al., 1998; Uetz et al., 2000). The
stoichiometric copurification to a high degree of purity in big amounts after affinity
tagging of a single subunit is the convincing proof for such an interaction. MED6 is so
far the only known bridge to the Mediator middle module (Baumli et al., 2005).
Fig. 11 – Architecture of the Mediator head module. (A) As shown by proteolysis and
subsequent subcloning the MED17 (SRB4) protein can be expressed as two variant MED17-
F1 and MED17-F2. The MED-F2 variant is sufficient to bind to MED6. It also binds to MED8,
which can be stoichiometrically copurified with the His6-tagged MED17-F2 variant. MED8 in
turn binds to the stable complex of MED18 and MED20, directly contacting at least MED18.
(B) Interaction map of the Mediator head module as established by yeast two hybrid GST-
pulldown assays, immunoprecipitation, mating type assays (Guglielmi et al., 2004) and large
scale copurifications (Baumli et al., 2005).
1.9. Binding assays point towards interactions between Mediator
subcomplexes and RNA Pol II
According to EM analysis the head is the major RNA Pol II interacting module
of Mediator. To test whether recombinant subcomplexes obtained in this work bind to
RNA Pol II, an excess of purified GST-MED17-F2/MED6!C-His (Fig. 12A) as well
MED18-His6/MED8/MED20 (Fig. 12B) was incubated with RNA Pol II (lacking Rpb4
and Rpb7) and subsequently subjected to gelfiltration. While free subcomplexes elute
in a separate peak from the column, some protein is still found co-eluting with RNA
Pol II, indicating a weak interaction. In the case of GST-MED17-F2/MED6!C-His it
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cannot be excluded that RNA Pol II binds unspecifically to GST. In addition the
heterodimeric complex has a great tendency to form aggregates, which elute in the
void volume. Thus the presence of MED17 (Srb4) in nearly every fraction would need
further control experiments. Results from individual MED17-F2 purifications indicated
that high salt concentrations in the purification buffer help to prevent aggregation of
MED17-F2.
A minor fraction of the heterotrimeric MED18/MED8/MED20 complex coelutes
with RNA Pol II and does not form any aggregates. The substoichiometric presence
of the trimer in the RNA Pol II elution peak points to a low affinity to RNA Pol II.
Nevertheless it is unlikely that the presence in this elution stems from a brought
elution profile of the trimeric complex since the signal of MED18 does not faint away
throughout the first four fractions. To test whether the trimeric complex is bound to
RNA Pol II a second gelfiltration of the RNA Pol II containing peak was performed.
Silver stained gels of the elution indicated that some trimeric complex is still present
(not shown), strongly indicating binding.
Fig. 12 – Size exclusion chromatography of RNA Pol II core-Mediator subcomplex
preparations. Mediator head module subcomplexes coelute with RNA Pol II on gelfiltration
columns: Superose6 elution profiles and SDS-PAGE analysis of gelfiltration fractions after
binding of RNA Pol II to GST-MED17-F2/MED6!C-His (A) and MED18-His6/MED8/MED20
(B). Arrows mark the MED18, MED8 and MED20 subunits in the coeluting fractions.
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2. Structural studies of the Mediator CDK8/Cyclin C module
The fourth module of Mediator, the CDK8/Cyclin C module, consists of four
subunits: MED12, MED13, as well as CDK8 and its cyclin partner Cyclin C. To
investigate the function of the CDK8/Cyclin C module, which is not permanentely
associated with Mediator, structural studies were performed on CDK8 and Cyclin C.
2.1. Cyclin C and CDK8 from S. pombe are obtained by recombinant
expression techniques
2.1.1. BLAST search discovery and cloning of Cyclin C and CDK8
Sequences from the S. cerevisiae proteins revealed long loops in an alignment
when compared with other species. Advantage was again taken from the fact that S.
pombe proteins often comprise fewer regions of low complexity, which might result in
a higher success rate for recombinant expression. The S. pombe homologs of the
CDK8/Cyclin C module subunits were not known at the beginning of this project. A
BLAST search determined potential candidates for Cyclin C (Fig. 13) and CDK8. The
orf numbers SPBC12D12.06 (Cyclin C) and SPAC23H4.17c (CDK8) were cloned
from S. pombe cDNA library.
Fig 13 – result of a BLAST search identifying a potential homolog of Cyclin C in S. pombe.
The WU-BLAST (www.ebi.ac.uk) was run with default parameters.
At a later stage, they were published as the Cyclin C and CDK8 homologs of
S. pombe (Samuelsen et al., 2003). Initially Cyclin C was cloned in a bicistronic
vector with CDK8 as well as in a monocistronic vector, the tag each time being
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located on the C-terminal end of Cyclin C. In the bicistronic system CDK8 was
expressed but was insoluble and would not bind to Cyclin C, which was well
expressed. Therefore a different strategy for CDK8 expression was set up.
2.1.2. CDK8 expression with the baculovirus Bac-to-Bac system
Apart from missing binding partners, another reason for eukaryotic proteins to
be insoluble or non-functional when expressed in bacterial cells can be missing post-
translational modifications. In most cases, bacterial cells are not able to provide the
eukaryotic protein with correct phosphorylations, glycosylations etc. In these cases
overexpression in a eukaryotic system is advisable. The principle of the baculoviral
system is the infection of insect cells with an insect cell specific virus where the gene
of interest was cloned behind the strong promoter of a gene nonessential for this
virus in cell culture.
For subsequent studies on CDK/cyclin interaction and crystallization trials the
expression of CDK8 from S. pombe with the help of the baculoviral system Bac-to-
Bac (Invitrogen) was established. The gene was cloned in the pFastBac1 vector and
an additional C-terminal His6-tag was introduced via the 5´primer. In a subsequent
transposon mutagenesis step combined with a classical blue-white selection, the
clone carrying the recombination event in the Dh10Bac strain was isolated. This
bacterial strain carries the viral genome on a so-called Bacmid of >135 kb. In the
positive clone, a big white colony on a selective blue-white medium, the CDK8 gene
was fused to the strong polyhedrin promoter and flanked by the transposon sites.
This step was controlled by PCR techniques using M13 primers and by CDK8
specific primers.
Production of the Bacmid DNA is a highly critical step in production of the
Baculovirus. The DNA needs to be very clean and highly concentrated. Handling of
this DNA has to be performed very carefully not to break it by shearing forces.
Manual DNA preparation techniques, as suggested by the Bac-to-Bac manual
(Invitrogen), did not lead to virus production, probably due to low DNA
concentrations. An adapted protocol for a Qiagen Midi Prep Kit helped to solve the
problem. In order to increase efficiency for elution of high molecular weight DNA, the
elution buffer needs to be heated to 65°C.
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For virus production in insect cells the recombinant Bacmid DNA was
transfected into SF9 insect cells (Novagen). The DNA to Lipid ration optimal for this
transfection was determined by evaluating infection efficiency. After the DNA is
transfected into the insect cells, the recombinant virus starts its production and the
expression of the protein of interest. The virus was harvested from the supernatant
and amplified in sequential rounds of virus infection, in which and multiplicity of
infection (MOI) were optimized stepwise. In figure 14 the establishment of the CDK8
expression technique is summarized and crucial steps are outlined.
Fig. 14 – Summary of the cloning and expression procedure for recombinant production of
CDK8 in SF9 insect cells. The CDK8 gene of S. pombe was cloned in the pFastBac1 transfer
vector before transforming this vector to DH10Bac E. coli cells carrying the viral genome on a
so-called Bacmid. After performing a blue/white selection the recombination event was
verified by PCR and the Bacmid DNA was isolated via an adapted protocol with a Qiagen kit.
For transfection into SF9 cells Lipofectin (Invitrogen) was tested for transfection efficiency
and an optimal DNA:Lipid ratio was established. Protein production after infection with the
recombinant virus was optimized by culture density, MOI, and infection time.
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Expression of CDK8 was tested with 20 ml cell culture experiments. Small-
scale Ni-NTA bead pulldown assays were analyzed by Western Blot for the best MOI
and infection time. For protein production 500 ml of log phase 80% confluent insect
cells were infected at a 1:7 ratio from the produced virus stock. Cells were harvested
48h post infection when production of the protein versus dead and broken cells was
optimal. A purification protocol for CDK8 was established consisting in sonication
lysis, Ni-NTA affinity chromatography and cation exchange column (Fig. 15). After
optimization steps the purification of CDK8 was promising but would still need further
improvement in order to reach yields suitable for crystallization.
Fig. 15 – Purification of CDK8. Infected insect cells were harvested 48 h post infection, lysed
by sonication. Cleared lysate was purified over a Ni-NTA column, elution fractions were
pooled and subjected to a Mono S column. Uninfected control and purification fractions were
analyzed by Western Blot with an anti-His antibody. The CDK8 band is marked with star in
the lysate from infected cells and the Mono S fraction.
2.1.3. Cyclin C can be recombinantely expressed in E. coli and purified
to crystallizable amounts
When cloned with a C-terminal His6-tag, expression of full-length S. pombe
Cyclin C yielded reasonable amounts of protein (for purification procedure compare
Fig. 16 and Materials and Methods). However it was very prone to degradation and
aggregation and could only be used for crystallization during two days. Cyclin C
formed small fragile crystals in 200mM MgFormate that were refined to approx. 70 x
70 x 70 "m3 diameter when grown in a buffer containing 25% glycerol, the minimal
concentration needed in the cryo-solution. The Cyclin C crystals only diffracted to a
maximum of 3.5 Å resolution with synchrotron radiation when they were harvested in
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their cryo-solution and plunged into liquid nitrogen within seconds. Molecular
replacement with these data failed. Since the crystals were so sensitive to any kind of
stress, it was suspected that some secondary structure in the protein would still
interfere with crystallization. To improve crystal quality, the protein was subjected to
limited proteolysis.
Fig. 16 - Purification of Cyclin C. Elution from the Ni-NTA column was optimized by an
imidazole gradient in the elution buffer. The peak containing the most pure Cyclin C (lane 1-
5) was applied to a Mono Q column before gelfiltration.
2.1.3.1. Limited proteolysis - the protease can make the difference
When testing proteins for stable domains via limited proteolysis several
proteases with different specificities should be used and compared. In case of the
Cyclin C using chymotrypsin or trypsin resulted in no defined proteolysis products
(Fig. 17, left panel). The protein cumulatively degrades over time without stable
intermediates suitable for subcloning. In contrast to that, subtilisin and proteinase K
treatment resulted in cleavage of four or 29 residues from the cyclin N-terminus (Fig.
17, right panel). A protein variant that lacked the N-terminal 29 residues was
insoluble, but a variant truncated by four amino acids produced crystals of improved
stability that diffracted to 3.0 Å resolution (Fig. 17). Molecular replacement with
known cyclin structures again failed.
Therefore the structure had to be solved by MAD analysis with a
selenomethionine-substituted crystal of a mutant protein that carried replacements of
two leucines to methionines. Using native diffraction data to 3.0 Å resolution, the
structure was refined to a free R-factor of 28.8% (Table 24). The final model shows
excellent stereochemistry and comprises all residues of Cyclin C except residues 1-5
(Table 24).
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Fig. 17 – Four amino acids on the N-terminus of Cyclin C interfere with crystal quality. Full-
length Cyclin C was subjected to proteolysis with trypsin and with proteinaseK. The tryptic
digestion did not reveal stable fragment, the protein appeared stable over time.
Crystallization of full-length Cyclin C resulted in fragile, weakly diffracting crystals. In
contrast, proteinase K digestion pointed to two potential variant, only the one lacking just the
first 4 amino acids resulted in soluble protein. This variant resulted bigger, more stable
crystals that diffracted to 3.0 Å.
2.1.3.2. Two leucines  in Cyclin C were mutated to methionines to
allow MAD phasing
When molecular replacement with known structures is impossible, the solution
of the phase problem can either be achieved from crystals derivatized with heavy
metals or crystals from proteins that contain a heavy atom incorporated through an
unusual amino acid. Selenomethionine can be used as such a variant heavy amino
acid (Budisa et al., 1995). For incorporation, methionine auxotroph bacteria are
grown in a minimal medium with selenomethionine forcing them to incorporate the
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amino acid in any protein they express. The 25 kD Cyclin C contains three natural
methionines including the N-terminal starting methionine. Ideally, methionines should
be located in the hydrophobic core because this augments the chances that they are
well ordered in the crystal. Since two methionines might not result in sufficient
phasing power, three additional targets for mutations were chosen: L60M, I125M,
and L186M.
Subsequently, the protein sequence was mutated using two-step PCR setups.
The resulting triple mutant unexpectedly yielded only insoluble protein. Testing all
combinations of two mutations a variant with an L60M and an L186M substitution
was found to be soluble. Interestingly, insolubility was caused only by the isoleucine
to methionine mutation, even though this isoleucine is highly conserved and located
in the hydrophobic core of previously solved cyclin structures.
The purification procedure for the mutant protein was adjusted since a
different elution profile from affinity chromatography columns was observed.
Expression levels in the methionine auxotroph strain in minimal medium were much
lower and the protein was very unstable. It resulted within a day to crystals of up to
150 x 150 x 150 "m3. Diffraction data sets with a maximum resolution of 3.5 Å were
measured with synchrotron radiation.
2.2. Solution of the Mediator Cyclin C structure
2.2.1. Data collection
Due to their limited size, low diffracting power and high solvent content
crystals had to be measured and screened at synchrotron radiation. Using the home
source (rotating anode, Rigaku), hardly any diffraction was visible. Probably due to
their high solvent content (72%), crystals were also very sensitive to harsh changes
and osmotic stress. Additionally they were very radiation sensitive. To optimize the
data collection strategy, MOSFLM (Powell, 1999) was routinely used to set up the
strategy. A highly redundant and complete data set needed around 100°. To avoid
local high x-ray doses that would trigger premature decay of the crystal, it was
absolutely crucial, to focus the beam on the detector instead of the crystal. Data sets
that were collected with a different setting were not complete, due to early crystal
damage. For phasing a MAD experiment was carried out around the selenium edge,
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collecting a 100° datasets first at the peak and subsequently at inflection and remote
wavelength (0.97977 Å, 0.98004 Å, and 0.94927 Å respectively).
2.2.2. Phasing and refinement
Molecular replacement with the program AmoRe failed with data sets from full-
length and mutant Cyclin C crystals. Cyclin structures might deviate substantially
outside the cyclin repeats and thus a search model was designed to use in molecular
replacement. To this end known cyclin structures from Cyclin A, Cyclin H and Cyclin
V were superimposed and only the core regions that possesa very similar backbone
fold were transferred into a new pdb-file. Coordinates were taken from Cyclin H
which shows the highest degree of sequence identity to Cyclin C. All non–identical
(Cyclin C to Cyclin H) residues were mutated to alanines. An alternative search
model consisted only of alanines. Failure of the program to phase the data set even
with the help of these search models was probably due to the very limited resolution
of the data, combined with a rather different topology of the molecule in question.
Phasing was achieved with the MAD experiment. Data from peak, inflection
and remote were processed and phases could be obtained with the help of the
SOLVE program. The peaks for all four ordered methionines – except for the N-
terminal methionine – could be located and served as a sequence marker for model
building. The “consensus cyclin model” that had been constructed for molecular
replacement was fit into the initial electron density and phase combination using CNS
helped to improve the electron densities. Due to the limited resolution the model was
built by hand, including more details and improving the phases at each step. To
prevent model bias the model was then truncated to a polyalanine chain and phases
from this model were combined with amplitudes from the native crystal data set.
Thereby the resolution was extended from 3.5 Å to 3.0 Å. This allowed building of the
atomic model by hand. Refinement of the structure with CNS (Brunger et al., 1998)
resulted in a free R-factor of 28.8% (Table 1). In the refined structure, 98.6% of the
residues fall in allowed regions of the Ramachandran plot, and none of the residues
are found in disallowed regions (Laskowski et al., 1993a).
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Table 24 – Cyclin C structure determination and refinement
Crystal Cyclin C (5-228) variant L60M/L186M, SeMet MAD Wild type, native
Data collection
Space group P3121 P3121
Unit cell axes (Å) A=b=91.9; c=90.9 a=b=91.7; c=90.1
Wavelength (Å) 0.97977 (peak) 0.98004
(inflection)
0.94927 (remote) 1.0725
Resolution (Å) 20-3.5 (3.6-3.5)
1 20-3.5 (3.6-3.5) 20-3.5 (3.6-3.5) 20-3.0 (3.16-3.0)
Completeness
(%)
99.4 (100) 99.5 (100) 99.7 (100) 99.4 (99.4)
Unique reflections 5866 (581) 5873 (581) 5885 (581) 9161 (1333)
Redundancy 9.12 9.04 9.29 6.0
Rsym (%) 8.6 (28.8) 7.4 (35.9) 5.8 (27.7) 8.1 (41.6)
Mean I/s I 23.6 (7.3) 23.8 (6.6) 24.5 (6.1) 17.0 (3.0)
f´ -7.0 -10.2 -2.8 -
f´´ 5.5 3 3.6 -
Refinement
Residues 227
2
RMSD bonds (Å) 0.008
RMSD angles (°) 1.3
Rcryst (%) 24.4
Rfree (%) 28.8
1The numbers in parenthesis correspond to the highest resolution shell.
2The final model comprises residues 6-228 of Cyclin C, and four additional residues at the C-
terminus that have been introduced during cloning as a spacer to the hexahistidine tag.
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2.3. Analysis of the Cyclin C structure
2.3.1. The structure of Cyclin C - canonical cyclin repeats
The structure of Cyclin C reveals two typical cyclin repeats consisting of five
helices each (H1-H5 and H1´-H5´ in repeat 1 and 2, respectively) (Fig. 18). The
length of some helices differs from that in cyclins A and H by several residues (Fig.
18). The individual cyclin repeats 1 and 2 can be superimposed on those of Cyclin H
with a root mean square deviation (RMSD) in main chain atom positions of 1.6 Å and
2.5 Å, respectively. The relative orientation of the two cyclin repeats is also similar to
that observed in cyclins A and H, so that both repeats of Cyclin C can be
superimposed with a RMSD of 2.7 Å in each case. The similar orientation of the two
repeats in cyclins C, H and A apparently results from conservation of the repeat
interface, which involves residues from helices H1, H2, H1´, H2´, and the conserved
inter-repeat linker (Fig. 18). In particular, the highly conserved residue R62 in H2
binds to the linker backbone carbonyl of residue F132 in the inter-repeat linker, as
observed in Cyclin H (Andersen et al., 1996a; Lolli et al., 2004), and additionally the
carbonyl of I134. In addition, residue Q50 in helix H1, Y139, and N164 in H2´ form a
cluster at the repeat interface. In contrast, the two cyclin repeats in the general
transcription factor TFIIB adopt a different relative orientation (Nikolov et al., 1995).
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Fig. 18 – Structure of Cyclin C and comparison with cyclins A and H. A, Schematic diagram
of cyclin primary structures. The two canonical cyclin repeats and the N- and C-terminal
helices are highlighted. Bars are drawn to scale. B, Ribbon model of the crystallographic
dimer of S. pombe Cyclin C. C, Structural comparison of cyclins C, H (Andersen et al.,
1996a) (PDB-code 1JKW), and A (Jeffrey et al., 1995) (PDB-code 1FIN). The proteins are
drawn as ribbon models. The color code for secondary structure elements is as in A and in
figure 19. Helices are numbered according to figure 19. D, Surface conservation. The surface
of the three cyclins in C is colored according to conservation as indicated in figure 19
Residues are highlighted in dark green, green, light green, and yellow, according to
decreasing degree of conservation. The view is as in C. Figures prepared with PYMOL
(DeLano Scientific).
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2.3.2. A mobile N-terminal helix
Cyclin C differs from known cyclin structures mainly outside the canonical
repeats. Before the first repeat, Cyclin C contains only one N-terminal helix (HN),
whereas Cyclin A additionally contains an extended N-terminal region (Fig. 18). The
C-terminus of Cyclin C is formed by the last helix in the second repeat, whereas
Cyclins H and A comprise additional C-terminal a. Cyclin C may thus be regarded as
a minimal cyclin, that only consists of the two canonical repeats and a specific HN
helix.
Helix HN in Cyclin C differs from that in Cyclins A and H in three aspects (Figs.
18C, 19). The helix is much shorter, adopts a different position, and is mobile. The
HN helix protrudes from the cyclin repeats, whereas the N-terminal helices of Cyclins
H and A intimately pack on the repeats with conserved residues (Fig. 18C-D)
(Andersen et al., 1996a; Lolli et al., 2004) The Cyclin C helix HN and the subsequent
loop show poor electron density, and have B-factors well above the average B-factor
for the two cyclin repeats (133 Å2 on average for residues 5-29; 75 Å2 for residues
30-228). However the N-terminal helices in Cyclins H and A show B-factors that are
comparable to the overall B-factors of the structures. Also, partial proteolysis of
Cyclin H does not cleave its N-terminal helix, indicating that it is an integral part of the
structure. The rigid nature of the N-terminal helices in Cyclin A, and also in a viral
cyclin, is further indicated by the observation that they adopt the same position in the
free cyclins and in their complexes with CDK2 (Card et al., 2000; Jeffrey et al., 1995).
2.3.3. Structure-based alignments.
Using the structures of Cyclin C (this work), Cyclin H (Andersen et al., 1996a;
Lolli et al., 2004) and Cyclin A (Card et al., 2000; Jeffrey et al., 1995) a structure-
based alignment of these different cyclin families using sequences from S. pombe, S.
cerevisiae, and human was prepared (Fig. 19). The structure-based alignment allows
identification of residues that only occur in a certain type of cyclin and are strictly
conserved there, and thus are candidates for cyclin-specific functions (see below).
The sequence comparisons also revealed that Cyclin C is the most conserved of all
cyclins. Human Cyclin C shares 71% and 29% of its residues with Cyclin C from
Drosophila melanogaster and S. cerevisiae, respectively, whereas the corresponding
percentages of identical residues are 32% and 21% in Cyclin A, and 40% and 26% in
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Cyclin H, respectively. In particular, the conservation of the second cyclin repeat is
much more extended in Cyclin C compared to other cyclins.
Fig. 19 – Structure-based sequence alignment of cyclin families C, H, and A. Structure-based
alignment of protein sequences of S. pombe Cyclin C (this study) with human Cyclin H
(Andersen et al., 1996a; Lolli et al., 2004), and human Cyclin A (Jeffrey et al., 1995).
Alignments were extended with Clustal W (Thompson et al., 1994) to three members of each
cyclin family, from S. pombe (Sp), S. cerevisiae (Sc), and H. sapiens (Hs), and were edited
by hand. Helical regions were determined with DSSP (Kabsch and Sander, 1983) and are
shown above the alignments as cylinders. Residues are highlighted in dark green, green,
light green, and yellow, according to decreasing degree of conservation. Residues in the
structural core, the repeat interface, and the crystallographic dimer contact are marked with
open circles, filled squares, and open diamonds, respectively. Residues that are strictly
conserved and at the same time specific for Cyclin C are marked with a red dot. Residues
involved in CDK recognition are marked with asterisks (compare table 25). Prepared with
ALSCRIPT (Barton, 1993).
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2.3.4. Modeling of the CDK8-Cyclin C pair.
A model of the CDK8-Cyclin C complex could be obtained in two steps. First,
Cyclin A in the human CDK2-Cyclin A complex crystal structure (Jeffrey et al., 1995)
(PDB-code 1FIN) was replaced with the S. pombe Cyclin C structure. To this end,
residues in Cyclin C that are near the CDK interface (residues 85-89, 94-98, and
118-129) were superposed onto their counterparts in Cyclin A (residues 263-267,
273-277, and 291-302, respectively). Second, a homology model of CDK8 was
constructed by replacing all differing CDK2 residues with program O (Jones et al.,
1991). Homology modeling was enabled by the high degree of sequence identity
between S. pombe CDK8 and human CDK2 (37%).
2.3.5. Aligning CDK classes within the protein family allows
determination of CDK8 characteristics and their mapping on the
CDK8 model
To determine specific features of the CDK8 class, a ClustalW alignment of 17
CDK sequences with two to four belonging to one class was performed. This
approach is practicable due to the high degrees of sequence identity and extremely
similar backbone fold that has been observed for CDKs in general (Lolli et al., 2004;
Russo et al., 1996; Tarricone et al., 2001). Similar to the “two dimensional alignment”
performed for the cyclin structures, this approach allows identification of residues that
are either identical in all analyzed CDKs, highly conserved among CDKs or highly
conserved (identical) only in one class of CDKs while not being present at this
position in other CDKs (Fig. 20). Projecting the identified residues from the alignment
onto the 3 dimensional model gives insight into the nature of these specificities.
Three of the residues cluster at the interface with the cyclin allowing speculations
about the nature of CDK-cyclin specificity (see below). Other residues cluster on the
opposite site of the kinase in an area that is known to interact with inhibitors.
Clustering of specific residues in patches can always indicate potential interaction
sites with binding partners important for complex formation and/or regulation. In
addition analysis showed that CDK8 contains two conserved insertions, absent from
other CDKs. The localization of the 9 amino acid insertion close to the activation loop
and the specific aspartate has point to an important function in CDK8 activity. With
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the PhD algorithm this insertion can be predicted to be an additional short helix in
CDK8.
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Fig. 20 (previous page) – Determination of class specific characteristics within the CDK
family. With the Clustal W algorithm (www.ebi.ac.uk) CDK7, CDK8, CDK9 and CDK2/CDK3
were aligned using sequences from S. cerevisiae, S. pombe, D. melanogaster and H.
sapiens at the same time. Thereby residues that are identical in all classes (blue), can be
distinguished from residues conserved among one class of CDK, but also present in other
classes (green) and residues that are specific and conserved only in one class of CDK (red).
Similarities within one class are marked in yellow. This analysis allowed the detection of
several CDK8 specific residues, among them several specific and highly conserved
insertions.
2.3.6. Specificity of CDK-cyclin interaction.
Comparison of the CDK-cyclin interfaces in the CDK8-Cyclin C model and the
CDK2-Cyclin A structure identified several highly conserved residues that are
generally involved in CDK-cyclin interactions (“general,” Table 25, Fig. 21). Five
invariant CDK residues are involved in these generally conserved interactions with
cyclin residues (V54, I59, R60, R160, L170 in S. pombe CDK8, Table 3), consistent
with previous observations (Andersen et al., 1996a; Jeffrey et al., 1995; Lolli et al.,
2004). These general interactions explain why Cyclin C can interact with both CDK8
and CDK3 (Ren and Rollins, 2004). In addition, residues in the CDK-cyclin interface
that are conserved only within a certain CDK or cyclin family were identified. Theses
“specific” residues may govern preferential interaction of a certain cyclin with a
certain CDK (Table 25). The two classes of interface residues cluster in two regions,
a “general” and a “specific recognition region” (turquoise and red, respectively, in Fig.
21B).
Specificity of Cyclin C for CDK8, as opposed to CDK2 or the two other CDKs
involved in transcription, CDK7 and CDK9, may be explained by several contacts of
side chains in the specific recognition region. In particular, several hydrophobic side
chains that pack against each other in the interface of the complex model are
complementary in size (Fig. 21C). For example, the side chains of L81 in the CDK8
model and F123 in the Cyclin C structure contact each other, and correspond to the
contact H71-H296 in the CDK2-Cyclin A complex structure (Fig. 21C, Table 25).
Residues M62 in the CDK8 model and A131 in the Cyclin C structure also contact
each other, and the corresponding contact I52-F304 is observed in the CDK2-Cyclin
A interface (Fig. 21C, Table 25). Similar complementary and specific pairs of
residues are observed at these positions in sequences of the pairs CDK7-Cyclin H
and CDK9-Cyclin T (Fig. 21, not shown).
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Fig. 21 – CDK-cyclin recognition. A, Model of the CDK8-Cyclin C complex, based on
the CDK2-Cyclin A structure (Jeffrey et al., 1995) (PDB-code 1FIN, compare text).
The proteins are represented as ribbon models with a superposed semitransparent
molecular surface. The black box outlines the region of the complex depicted in C. B,
“Book view” of the model in A. The two protein representations were rotated by 90
degrees in opposite directions to allow viewing of the interface. Surfaces of residues
that constitute the “general” and the “specific recognition region” of the CDK-cyclin
interface were highlighted in turquoise and red, respectively (compare text and Table
2). C, Comparison of selected residues in the specific recognition region of two CDK-
cyclin interfaces. Residues of the CDK2-Cyclin A structure (PDB-code 1FIN) are in
light pink, and residues in the CDK8-Cyclin C model are in red.
This analysis however does not account for possible alternative interactions
and rearrangements in the CDK-cyclin interface, which may be crucial to optimize the
surface complementarity. For example, cyclins A and C apparently form alternative
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salt bridges at the interface with their cognate CDKs. A conserved basic residue in
the kinase (K56 in CDK2, R66 in CDK8) is bound by the non-conserved aspartate
D305 in Cyclin A, but may be bound by D130 in Cyclin C, which is offset in register
by two residues (Table 25). Indeed side chain rearrangements in a CDK-cyclin
interface have been observed in the recent structure of a CDK2/cyclin E1 complex
(Honda et al., 2005), in which K56 of CDK2 adopts a different conformation and does
not to interact with the basic residue R225 in cyclin E.
Table 25 – CDK-cyclin interactions1
CDK2 structure
(Jeffrey et al.,
1995)
CDK8 model Cyclin A structure
(Jeffrey et al., 1995)
Cyclin C structure
General recognition region
V44 (backbone) V54 (backbone) K266
E295
K88
E122
I49 I59 K266
L263
L306
K88
L85
L133
R50 R60 F267 (backbone)
K266 (backbone)
V89 (backbone)
K88 (backbone)
R150 R164 F267 (backbone)
E268 (backbone)
E269 (backbone)
V89 (backbone)
E90 (backbone)
E91 (side chain)
V154 L170 T316
E268
T140
E90
Specific recognition region
H71 L81 H296
-
F123
I126
I52 M62 F304 A131
S53 M63 F304 (backbone)
F267
L306
-
A131
V89
L133
F132 (backbone)
K56 R66 T303
F304
D3052
D1302
A131
-
A151 L164 A307
F267
I134
-
G153 R166 Q313
-
T140
H136
1Depicted are CDK residues that have at least one atom within 4 Å of an atom of the cognate
cyclin. For the general recognition region, cyclin residues are only included if the contacts are
observed in the CDK2-Cyclin A structure and in the CDK8-Cyclin C model.
2Possible alternative salt bridges see text.
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2.3.7. Conserved surfaces.
Specificity for CDK-cyclin interaction may also arise from additional protein
subunits that could bridge between the kinase and the cyclin, such as MED12 (Srb8)
and MED13 (Srb9) in the case of the CDK8-Cyclin C pair. To detect possible
interaction sites for other proteins on cyclins C, H, and A, their molecular surfaces
were colored according to conservation over species (Fig. 18D). A conserved and
Cyclin C-specific surface patch is found just before the mobile helix HN, comprising
the exposed aromatic residues Y5 and W6 (Fig. 18D). Whereas the N-terminal helix
of Cyclin A contributes to the interface with CDK2, helix HN in Cyclin C points away
from the kinase-binding surface (Figs. 18, 21), and cannot contribute to CDK8
binding. In the crystals, the N-terminal region of one molecule contacts the second
cyclin repeat of its neighbor, resulting in a crystallographic dimer that buries several
hydrophobic surface residues in its interface (L186, L200, A208, F209, I212, V215,
I219) (Figs. 18B, 19). The dimer may pre-exist in solution since deletion of helix HN
results in an insoluble protein, possibly because hydrophobic residues in the dimer
interface are exposed (not shown). Since most of the hydrophobic residues and the
HN helix are not conserved, the dimer is apparently not physiological. In the intact
CDK8/Cyclin C module, the N-terminal region of Cyclin C could therefore bind
MED12 (Srb8) or MED13 (Srb9), and, given its mobility, may change its position
upon interaction with the target protein.
2.3.8. A conserved groove unique to Cyclin C.
Cyclin C also shows a highly conserved surface groove between the two cyclin
repeats (Fig. 18D). The corresponding region in cyclins A and H is not conserved,
and the conserved groove in Cyclin C is thus likely to have a function specific for this
type of cyclin. Indeed, five of the surface residues in this groove are invariant among
Cyclin C family members, but are not conserved and do not occur in any other cyclin
family (residues I33, R49, W160, D165, and Y167) (Fig. 19, red dots; Fig. 22A).
Since the groove is near the active site and the activation segment of CDK8 in the
CDK8-Cyclin C model (Fig. 22), it may bind substrates and could contribute to CDK8
specificity. Indeed, Cyclin A has a conserved surface patch that binds kinase
substrates, albeit at a different location (Fig. 18D) (Schulman et al., 1998).
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2.3.9. Possible mechanisms of CDK8 activation.
CDKs are generally activated in two steps that include binding of the cyclin,
and phosphorylation of a conserved threonine in the CDK activation segment (T160
in human CDK2) (Pavletich, 1999). Interaction of the phosphothreonine side chain
with three conserved arginines (Fig. 22B) triggers a conformational change that
results in full kinase activation. All CDKs carry a threonine or a serine at the
phosphorylated position, except CDK8, which has a conserved aspartate (D176 in S.
pombe). The aspartate could however mimic a phosphothreonine, because of its
negative charge and similar extension, and could interact with the three arginines,
which are also conserved in CDK8 (Fig. 22C). This model however requires that the
activation segment of CDK8 adopts the same conformation as in CDK2, which may
not be the case, because it is three residues longer, and since CDK8 contains a
specific ten-residue insertion near the activation segment (Fig. 22A, purple spheres).
Indeed, the activation segment of CDK7, which is also longer, adopts a different
conformation (Lolli et al., 2004). Its phosphorylated threonine is not coordinated by
the three conserved arginines.
An alternative mechanism of CDK8 activation is suggested by the Cyclin C
structure. In the CDK8-Cyclin C model, the negatively charged side chain of the
exposed glutamate E91 in Cyclin C is in a position to interact with the arginine cluster
in CDK8, and could in principle activate the kinase in trans (Fig. 22C). The side chain
of the corresponding residue in Cyclin A (E269) points in the opposite direction,
where it forms a hydrogen bond with T231 (Fig. 22B). This hydrogen bond cannot be
formed in Cyclin C, because the residue corresponding to T231 is a valine in Cyclin
C (V52) (Fig. 22C). Cyclin C could in principle act similar to a viral “supercyclin” that
can activate CDK6 without phosphorylation of the activation segment (Schulze-
Gahmen and Kim, 2002). Finally, the exposed E91 of Cyclin C could also be involved
in determination of CDK8 substrate specificity, similar to a conserved glutamate in an
activator protein of CDK5 (Tarricone et al., 2001).
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Fig. 22 – Structural features relating to CDK8 activity. A, Model of the CDK8-Cyclin C
complex in figure 21A.. The model is shown as a ribbon diagram, with a semitransparent
surface colored according to conservation of Cyclin C, as in figures 18, 19. The asterisk
indicates the location of the kinase active site. The CDK activation segment is in green and
includes the conserved aspartate D176 (red sphere). The beginning and the end point of a
ten-residue CDK8-specific insertion are marked with purple spheres. The conserved surface
groove in Cyclin C is indicated. B, Detailed view of the region around the activation segment
in the structure of Cyclin A bound to CDK2 phosphorylated at residue T160 (Russo et al.,
1996) (PDB-code 1JST). The phosphothreonine is in red, and the three conserved arginines
(arginine cluster) that it coordinates are in blue. A hydrogen bond between cyclin residues
E269 and T231 is shown as a dashed line. C, Possible mimicry of phosphorylation in the
CDK8 activation segment. The CDK8-Cyclin C model in A is oriented as in B. A conserved
aspartate in the CDK8 activation segment that could mimic a phosphothreonine is in red
(D176). A glutamate in Cyclin C that could bind the CDK8 arginine cluster in trans is in pink
(E91). The hydrogen bond depicted in B cannot be formed, since the donor T231 in Cyclin A
is replaced by a valine in Cyclin C (V52, pink).
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Discussion and future directions
1. The Mediator head module: dissecting a protein-protein network
A core Mediator consists of subunits from the head and middle modules and is
responsible for contacts with the general transcription machinery, RNA Pol II and
GTFs. Core Mediator enables 4-fold activation of transcription in nuclear extracts,
compared to 18-fold activation for the complete Mediator (Liu et al., 2001; Spahr et
al., 2000; Spahr et al., 2001). The composition of the Mediator in several species, its
conservation, and the crucial role it has in transcription activation are generally
accepted. Nevertheless, the molecular mechanism of this function remains
enigmatic, mainly due to lack of detailed structural information. Interaction of head
and middle module with RNA Pol II was shown by EM techniques, suggesting that
the head module is the major RNA Pol II-interacting module.
Over the last years pull-down assays, genetic and yeast two hybrid screens,
coexpression of subunits in insect cells, coimmunoprecipitation, and the split ubiquitin
assay (Guglielmi et al., 2004; Ito et al., 2001; Kang et al., 2001; Koh et al., 1998; Lee
et al., 1998; Uetz et al., 2000, Gromoller and Lehming, 2000) led to interaction maps
of Mediator and the Mediator head module. With the help of bi- and tricistronic
expressions and cotransformations, large-scale copurifications could be tested and
thereby multiple direct protein interactions within the head Module were determined
and verified. Such copurification can successfully map strong and specific direct
protein-protein interactions, as demonstrated by the structure determination of the
MED7/MED21 complex (Baumli et al., 2005). The copurification assay with only one
tagged protein is very stringent, since many different non-specific competitor proteins
are present in the E. coli lysate, since the stoichiometry of the complexes can be
estimated with Coomassie-stained gels, and since the protein-protein complexes
must persist over several copurification steps.
1.1. MED17 – domains and interactions
Subunits of the Mediator head module are mostly insoluble when
recombinantly expressed as single subunits in the E. coli system. The largest subunit
of the head module, the essential MED17 (Srb4), had been suggested previously to
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form a kind of scaffold protein in the organization of the module (Koh et al., 1998).
Therefore it was chosen as a starting point for structural analysis. Expression of
MED17 as a single subunit yielded enough protein to start a domain analysis using
the limited proteolysis approach. As a result, two variants of MED17 were designed,
the F1 and F2 fragments. Secondary structure prediction, alignment studies and data
available from genetic and biochemical studies (Koh et al., 1998, Lee et al., 1998,
Thompson et al., 1993) point to a great importance of the F2 fragment, since it
comprises potential interaction sites with activators like Gal4, with other Mediator
subunits like MED6, the srb-mutation as well as all sequences essential for viability
(Fig. 2B). It was therefore used in a systematic bicistronic expression and purification
screen with the remaining subunits of the Mediator head module. The interaction of
MED17 (Srb4) with MED6 that had been observed before in a GST pulldown assay
(Lee and Kim, 1998) was verified by copurification of the two subunits over two
subsequent affinity chromatography steps. A very recent study had also determined
this interaction in a yeast two-hybrid analysis (Guglielmi et al., 2004). Successful
purification of the complex was independent of the order of the affinity columns. As it
could be expected from the genetic data, the weakly conserved N-terminal F1
fragment of MED17 was not required for interaction. For MED6, a C-terminal
truncation mutant without the non-conserved C-terminus was used (residues 1-214)
which was sufficient for binding. Genetic studies consistent with this result point to an
interaction of MED6 (med6 ts2 mutant allele: Q49L, I68L, L94P, F125Y, R132G,
F194L) with MED17 in an area around residue 286 (srb4-101 allele: E286K) (Lee et
al., 1998).
With the same approach of copurification after coexpression the interaction of
MED17 and MED8 could be shown for the first time. Coexpression of MED17-F2 with
MED8 greatly increases expression and solubility of MED17-F2 (Srb4-F2) and MED8
is purified stoichiometrically along with MED17-F2-His6 after an affinity
chromatography step. Again the residues 241-687 of MED17 (F2 fragment) are
sufficient for the interaction.
Bicistronic expression of the MED17-F2 fragment either with MED20 (Srb2),
MED19 (Rox3), MED11, or MED22 (Srb6) did not lead to improved expression or
solubility. Thus, a large-scale copurification of these complexes was not achieved.
Since binding of MED17 to these subunits was predicted by other studies (Kang et
al., 2001; Koh et al., 1998; Lee et al., 1998) it is important to emphasize that the
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copurification assay is very stringent and selects for specific binding of proteins.
Especially if several subunits contribute to an interaction network in vivo, lacking of
subunits could prevent proper folding and complex assembly in the recombinant
system. The MED17 protein and even the MED17-F2 fragment are big polypeptides
of 75 and 50 kD respectively. Thus, if MED17 or MED17-F2 is coexpressed with only
one binding partner there is still a high probability that large areas of this scaffold
protein are unfolded or hydrophobic patches important for interaction are exposed.
On the other hand one could speculate on a rather large interface between MED17
and MED6 or MED8 since the bicistronic expression already brings great
improvement to solubility.
Another possibility is the binding of head module subunits to the MED17-F1
fragment, which had not been tested here. Since sequences in the F1 fragment are
not essential for viability (compare Fig. 2) in yeast (Koh et al., 1998) but comprise
stretches that are conserved in evolution it is appealing to speculate that non-
essential subunits like MED20 (Srb2) could bind to these sequences. Indeed, binding
of MED20 (Srb2) to MED17 (Srb4) has previously been detected in co-
immunoprecipition assays (Kang et al., 2001; Koh et al., 1998; Lee et al., 1998).
Thus, interactions between the MED17-F1 fragment and head module subunits
would be a good target for further bicistronic expression trials. Using the MED17-F1
fragment would also take advantage of the high expression and solubility of this
fragment when expressed from a monocistronic vector. Failure of crystallization of
MED17-F1 could be due to partial misfolding or to sequences interfering with
crystallization, but might as well simply results from limited trials in finding
crystallization conditions. Recent crystallization trials on head module subunits with a
crystallization robot point towards a general necessity for high salt concentrations of
Mediator head module proteins.
1.2. The MED20/MED18/MED8 proteins form a stable subcomplex within
the Mediator head module
A proof of principle for bicistronic expression is provided by comparing MED20
(Srb2) expression levels in combination with MED17-F2 (Srb4) versus MED18
(Srb5). In both cases the gene was cloned untagged in the same vector. Bicistronic
expression with a tight interaction partner for MED20 (Srb2), namely MED18 (Srb5),
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leads to dramatically increased expression levels and solubility (Fig 6A). While
MED20 was expressed but insoluble in combination with MED17-F2 (Fig. 4A), it
forms a stoichiometric complex with MED18. The stability of the complex over
several purification columns and for weeks at 4°C can be regarded as the best proof
for interaction for these two subunits. Conditions for the formation of initial
microcrystals hint to high salt concentrations. For crystal improvement additional
more specialized screens might already bring about the desired result.
MED18 variants designed according to limited proteolysis results were
insoluble. From an alignment with the soluble S. pombe MED18 (Srb5) homolog it
was inferred, that N-terminal stretches are conserved before a long loop in the
MED18 S. cerevisiae sequence. Cleavage of the complete N-terminus, as performed
according to limited proteolysis results, could thus interfere with proper protein
folding. Consistent with proteolytic data a usefull strategy might thus be the removal
of the internal loop, leaving the conserved N-terminal sequences intact.
It was shown that MED8 binds to the MED20/MED18 subcomplex (Fig. 6c) - a
stoichiometric trimeric subcomplex is stable over several copurification steps.
Nevertheless, the MED8 protein is not as well expressed and excess of the
MED20/MED18 complex needs to be separated from the trimeric complex by
gelfiltration. The subcomplex context of MED20/MED18 is not sufficient to assure
complete MED8 stability, in a proteolysis assay it is rapidly degraded. These results
fit perfectly with the observation that MED8 binds as well to MED17 (Srb4) and that
this binding is already sufficient to greatly improve complex solubility. In addition, the
interaction between MED8 and MED18 (Srb5) is limited to a very short C-terminal
sequence (L. Lariviere, unpublished data).
1.3. Towards reconstitution of the Mediator head module and the Mediator
core
Combination of results from bi – and tricistronic expressions led to the
postulation and proof of higher order head module subcomplexes. Since MED6 binds
to MED17-F2, which in turn binds to MED8 and this to MED20/MED18, a
coexpression of two vectors and purification via a GST-tag on MED17-F2 was used
to purify a pentameric complex of these subunits (Fig. 10). The purified pentameric
subcomplex was very prone to aggregation and was not stoichiometric indicating that
hydrophobic patches or unordered sequence strechtes, possibly resulting from
Discussion and future directions
84
missing interaction partners, still interfered with the preparation of a homogenous
sample. The presence of the rather big GST-tag on MED17 might also interfere with
proper complex assembly. A smaller tag, e.g. His-tag or FLAG tag, possibly on a
different subunit (a C-terminal His-tag on MED18 was shown to work in the
tricistronic expression), would represent a less invasive stratgey. Nevertheless, it was
shown that recombinant overexpression of multiple subunits from Mediator head
module is possible and the predicted interaction pattern was proved. Since the
coexpression of five head module subunits was shown to be possible, the most
promising strategy can now be the recombinant expression of the complete head
module, thereby circumventing aggregation due to missing subunits. To this end the
eight genes coding for head module subunits should be combined on tri- or
quatricistronic vectors for coexpression such that known subcomplexes are coded on
the same vector.
Most interesting for structural and functional studies on Mediator will be the
purification of the core Mediator, comprising the essential subunits. In the presented
work it was shown that MED6 binds to MED17 and that this subcomplex can be
purified stoichiometrically in larger amounts. These results are consistent with a
previously observed functional interaction and a recently published yeast two hybrid
interaction map (Guglielmi et al., 2004; Lee and Kim, 1998). MED6, which is an
integral part of the head module (Lee and Kim, 1998) and additionally binds directly
to the MED7/MED21 subcomplex of the middle module (Baumli et al., 2005) (Fig.
11). This interaction of MED21 with MED6 is apparently essential in vivo (Gromoller
and Lehming, 2000). In conclusion, MED6 physically bridges between the two
Mediator core modules, interacting with MED17 in the head module and with the
MED7/MED21 heterodimer in the middle module. Extended loop regions in MED6
indicate a strong intrinsi flexibility that may be crucial for observed large
rearrangements within Mediator when it comes to Pol II binding (Asturias et al., 1999;
Davis et al., 2002).
Thus, combination of subcomplexes obtained in this study with subcomplexes
from the Mediator middle module would make recombinant production of the
Mediator core an intermediate term goal. Initial coexpression results with MED21,
MED6, MED17 and MED8 (not shown) were already successful, a drawback was
again low expression yields and complex aggregation due to missing binding
Discussion and future directions
85
partners, which can be overcome by stepwise analysis and addition of the minimal
combination of subunits for stable purification as shown.
1.4. Structure-function studies on Mediator-RNA Pol II complexes
A future goal in studying the mechanism of Mediator will be structural data of
Mediator or individual subunits binding to RNA Pol II. Even though direct binding of
Mediator to RNA Pol II has been shown from in EM data, it is still an open question
which subunits are involved in this interaction. Genetic data from the srb genes
indicate interaction of these subunits via the CTD, but that could be direct or indirect.
A yeast two-hybrid approach for interaction studies between individual subunits of
Mediator with individual RNA Pol II subunits was not successful (Guglielmi et al.,
2004). A possible combined interaction with between various even small subdomains
as well from Mediator as from RNA Pol II can probably not be detected efficiently with
this method. Results from EM studies imply that the Mediator head module is the
major RNA Pol II interacting submodule of Mediator. The recombinantly purified
subcomplexes were thus used in interaction studies with RNA Pol II in order to nail
down the interacting subunits, for the use in functional and for obtaining structural
data. In preliminary experiments it was shown that the MED17 (Srb4)-MED6
subcomplex coelute with RNA Pol II from a gelfiltration column. These data will have
to be validated due to limited concentration of MED17-MED6. It was also shown that
after an incubation time the trimeric MED8/MED20/MED18 complex coelutes with
RNA Pol II from a gelfiltration column whereas free trimeric complex elutes in a well
separated peak (Fig. 12). The complex is not stoichiometric, indicating weakness of
the binding. Whether MED8 is required for binding or whether the non-essential but
highly conserved MED20/MED18 complex alone binds to RNA Pol II can now be
easily investigated by repeating the binding experiment with the dimeric complex.
Although the med20 (srb2) and med18 (srb5) genes are dispensable for cell viability,
in vitro transcription assays using nuclear extracts from deletion mutant strains
reveals that MED20 and MED18 have important roles in basal transcription (Koleske
et al., 1992; Thompson et al., 1993; Thompson and Young, 1995), which would be
consistent with binding to RNA Pol II. On the other hand MED8 could be responsible
for binding RNA Pol II:  the C-terminal region was determined to be responsible for
Med18 binding (Guglielmi et al., 2004) as well as MED17 binding (Guglielmi et al.,
2004). The N-terminal sequences contain large conserved stretches (Boube et al.,
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2002) that could be responsible for further interactions, namely to MED20 (Guglielmi
et al., 2004). The high sensitivity of MED8 in the trimeric complex towards protease
digestion observed in this study hints to the importance of the MED8-MED17
intercation. Additional N-terminal sequences could be responsible for RNA Pol II
binding. Such questions can be addressed by iterative binding assays of RNA Pol II
to head module subcomplexes of different compositions.
The binding of smaller but homogenously purified subcomplexes to RNA Pol II
will additionally be beneficial for structural studies on Mediator-RNA Pol II interaction.
On one hand, these samples can be used for EM studies promising higher resolution
than the non-homogenous material that is mostly obtained from native purifications.
Varying the combinations of subunits will then lead to a detailed interaction map
between Mediator and RNA Pol II. On the other hand use in cocrystallization trials
can result in atomic models of the interaction. Using high-resolution structural data of
RNA Pol II-Mediator complexes to design appropriate functional studies could bring
about the change in understanding the enigmatic mechanism of Mediator function.
2. The Mediator CDK8/Cyclin C module: implications of the Cyclin
C structure for function
The CDK8/Cyclin C pair (Srb10/Srb11 in yeast) associates with MED12 (Srb8)
and MED13 (Srb9), to form a fourth module of the Mediator that is present in a
subpopulation of Mediator complexes. This Mediator module phosphorylates the
CTD, is conserved among eukaryotes, and is a target of signal transduction
pathways (Borggrefe et al., 2002; Boube et al., 2002; Liu et al., 2001; Samuelsen et
al., 2003). To elucidate the characteristics of this CDK/cyclin pair implied by its
association in a tight complex, its different regulation due to no abundance fluctuation
by the C-type cyclin and a missing phosphorylation site on CDK8, and its role in
activation and repression of transcription, this work presented the structure of Cyclin
C from S. pombe along with an interaction model with its kinase.
2.1. The Cyclin C structure
In contrast to the subunits of the Mediator head module it was possible to
express and purify Cyclin C in a monocistronic expression system. Bicistronic
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expression of CDK8 and Cyclin C failed. The kinase was expressed but mostly
insoluble, the soluble fraction did apparently not bind to the cyclin, which carried the
affinity purification tag. This could be due to missing posttranslational modifications or
lack of proper folding in the E. coli system. It could also indicate that the MED12 and
MED13 subunits stabilize this complex. Therefore an expression and purification
protocol for CDK8 with a baculoviral system was established. In order to obtain
amounts of CDK8 suitable for structural studies, large-scale expression with this
system are the method of choice.
The purified full-length Cyclin C crystallized to small fragile crystals, that were
very sensitive to any stress and diffracted only to 3.5 A. As a first indication of
substantial differences in the cyclin fold molecular replacement (AMoRe) with these
data using a minimal consensus cyclin model that had been designed after extensive
alignments of known cyclin structures failed. Later on, the structure revealed rather
high RMSD values especially for the second cyclin repeat (2.5 Å), which might have
been the cause. It is important to note that molecular replacement relies on relatively
high sequence identity rates as well as good resolution since otherwise noise peaks
in the Patterson map interfere with detection of the correct rotation function. Both
could not be provided with Cyclin C (S. pombe) since it shares only 19% of the
sequence with human Cyclin H and since the resolution was very limited. Thus, the
calculated potential solutions for the rotation function did not reveal an outstanding
best hit. Improved likely-hood enhanced programs that are becoming available might
have been able to solve such a problem.
The solution of the Cyclin C structure represents a nice example on how just a
few residues might interfere with crystal quality and thus resolution. In contrast to
proteolysis assays using trypsin, cleavage with proteinase K pointed to two candidate
fragments suitable for crystallization. Whereas removal of the first 29 residues
resulted in insoluble protein removing just the first four amino acids drastically
improved crystal quality and was the basis for building an atomic model of Cyclin C.
Analyzing the obtained protease cleavage sites in the molecular model of Cyclin C
reveals the drawbacks as well as the potentials of the limited proteolysis assay: The
protease cleaved in a loop connecting the N-terminal helix with the first cyclin repeat.
B-factors indicate a high flexibility of this region that probably interferes with
crystallization. Removal of such an N-terminal or C-terminal helix would usually be
considered as a good candidate for a crystallizable variant. But, probably due to the
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highly hydrophobic surface of Cyclin C when expressed without binding partners, the
protein uses the helix to dimerize and form a “handshake” interaction thereby
shielding hydrophobic patches (Fig. 18B). Cleavage of the helix prevents
dimerization and thus leads to insoluble protein, which can be explained by the
crystal structure. A similar observation would be expected from cleavage of
accessible loops that do not connect independent domains of proteins but rather links
to secondary structure elements within the same domain, for example serving as a
binding partner platform. This is one of the major reasons why constructs from
protease assays may result in insoluble protein (as observed for example with
MED18). On the other hand, the N-terminal four amino acids that formed the tip of
this “handshake” interaction in the crystal contact made the crystal to fragile due to
high flexibility. The assay revealed this cleavage site and removal probably helped to
stabilize the crystal contact yielding greatly improved diffraction data.
2.2. Cyclin C differs from known cyclin structures
The exposed position of the N-terminal helix in Cyclin C that is probably a
crystallization artifact could nevertheless have implications for function. In contrast to
classical cell cycle cyclins like Cyclin A or cyclin E, where the N-terminal helix forms
part of the interface with the kinase, a different fold for the N-terminal helix had been
observed for the previously solved C-type cyclin structure, namely the structure of
Cyclin H. In the case of Cyclin H the N-terminal helix binds tightly to the cyclin repeat.
As shown, average B-factors in this area are even lower than in the rest of the
protein. Additionally, analysis revealed an interaction highly specific for Cyclin H with
residues that are absolutely conserved and at the same time specific for Cyclin H
(residues R23, N27, and E53 in human Cyclin H). The authors of the Cyclin H
structure state that Cyclin H is not able to activate CDK7 without this helix even
though it does not contact the kinase and that this might be due to loss of structural
integrity when the protein is mutated. According to B-factor and specificity analysis
performed in this work this is likely the case. For the solved cell cycle cyclins it had
been observed that the cyclin represent a very rigid structure, where localization of
the N-terminal helix is unaltered irrespective of the kinase being bound or not (Card
et al., 2000; Jeffrey et al., 1995). With Cyclin C, a third variant of N-terminal helix is
presented. Apparently it does not fold towards the interface with the kinase, although
this cannot be completely ruled out to be the result of the crystallization artifact. The
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fact that no highly conserved residues for the packing of the helix against the C-
terminal cyclin repeat were identified together with high B-factors as well as the
shortness of the helix point to a different role of the N-terminal helix in Cyclin C. In
this context it should be emphasized that the Cyclin C can be regarded as a minimal
cyclin. It basically consists only in the cyclin repeats with the additional small N-
terminal helix whereas all other cyclins comprise additional N and or C-terminal
sequences (compare Fig. 18) of unknown function that are quite long in some cases
(e.g. Cyclin A and Cyclin T). It is imaginable that the additional proteins in the
Mediator CDK8/Cyclin C module fulfill functions of such domains. Especially the N-
terminal helix could adopt a similar fold as observed in the closely related Cyclin H
when a binding partner is present. This would also be consistent with an observation
that all C-type cyclins possess a conserved W on the N-terminus (Fig. 19), which – in
Cyclin H – is involved in the folding. On the other hand, the additional sequences
might play a role in the periodical destruction of cyclin via ubiquitination that is
responsible for the cycling of cyclins in the cell cycle. Indeed, Cyclin C lacks a
destruction box and a PEST sequence, rich in proline (P), glutamate (E), serine (S),
and threonine (T) that are present in Cyclin A in these regions (Jacobs et al., 2001).
2.3. A structural model of CDK8 identifies targets for functional analysis
The structure of CDK8 can be modeled due to a high degree of sequence
identity among CDKs (37% in the case of CDK2, pdb code 1FIN) and the observation
that the backbone fold of all CDK structures solved so far was highly similar (Jeffrey
et al., 1995; Lolli et al., 2004; Pavletich, 1999; Tarricone et al., 2001). In combination
with an extensive alignment filtering the highly CDK-type specific residues against
generally conserved residues, this method allows some predictions on the
characteristics of CDK8. Most interesting is the presence of two specific insertions
(Fig. 20, 22) the longer one is predicted to be an additional helix. This helix would be
located close to the active site. It is easy to imagine the helix being involved in
substrate specificity and regulation of CDK8, especially regarding the missing
activating phosphorylation site in this kinase class. It remains to be investigated
whether the conserved aspartate in the position of the phoshorylation site mimics the
phosphorylated state and forms a cluster with the three conserved arginines (Fig.
22C). Modeling showed that the activation segment is 3 residues longer in CDK8 and
might thus exhibit a different fold, involving for example the additional helix. A
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potential activation of CDK8 in trans by the exposed E91 (Fig.22C) of Cyclin C
provides an interesting target for mutational analysis.
Other highly conserved and specific residues cluster in two patches on the
CDK8 surface. The first one, with three amino acid residues, is located at the
interface with Cyclin C and is probably involved in recognition of it as it was shown by
comparison of known CDK/cyclin interfaces (Fig. 21). The second patch is located in
an area responsible for inhibitor binding in cell cycle cyclins. Again a clustering of
specific residues in this area points to the differences in regulation of this kinase. A
similar observation was made in the recently published CDK7 structure (Lolli et al.,
2004). The authors state that this area deviates substantially from the inhibitor-
binding site in CDK2 and does thus not bind the inhibitor. For CDK7 the region is a
good candidate patch for binding MAT1, which is suspected to bind the kinase rather
than the cyclin (Andersen et al., 1996b). Binding assays with mutant CDK8 from
baculoviral expression and functional studies on substrate specificity after deletion of
specific insertions should provide an interesting insight in the function and regulation
of the Mediator kinase.
2.4. Analysis of CDK-Cyclin interface suggests the structural basis for cyclin
promiscuity
Comparison of the modeled CDK8/Cyclin C interface with known CDK/cyclin
interfaces and combination of the results with the data alignment led to the discovery
of two parallel patches in the interface: a general recognition patch that could be
responsible for nonspecific CDK/cyclin recognition and a patch of specific
interactions where a size-complementary interface could be involved in specific
recognition of the individual cyclin (Fig. 21). This could explain why, apart from a
different time resolution of presence of cyclins, specific CDK/Cyclin Complexes are
formed. The C-type cyclins involved in transcription do apparently not fluctuate in
abundance throughout the cell cycle. Cyclin A is able to activate CDK7, but this
activation is less efficient than with the correct cyclin partner (Andersen et al., 1996a;
Lolli et al., 2004). An association of Cyclin C with the human CDK3 during cell cycle
(Ren and Rollins, 2004; Sage, 2004) would be imaginable in this context. It should be
mentioned that the intrinsic capacity of the cyclin to modulate CDK specificity has
recently been emphasized (Loog and Morgan, 2005). In yeast different cyclins that
are active throughout the cell cycle associate with the same CDK. This association
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itself leads to modulated enzyme activity and could in principle be achieved through
alternative conformations in the interface.
2.5. A highly specific groove of Cyclin C
Another mechanism of achieving substrate specificity through the cyclin are
substrate recognition patches. Cyclin A possesses a highly specific hydrophobic
patch responsible for binding of the RXL motif of substrate proteins (Kontopidis et al.,
2003; Schulman et al., 1998). The highly specific groove between the two cyclin
repeats discovered in this work could be part of an analogous mechanism for Cyclin
C. The different nature of the patch would underline the different requirements for the
CTD as substrate, which does probably not contain separated phosphorylation and
substrate recognition motifs due to its repetitive nature. Cyclin Ts exhibit a prolonged
C-terminal domain that has been shown to be involved in CTD binding via a His-
patch (Kurosu et al., 2004; Taube et al., 2002). Alternatively the groove could be
involved in establishment of the multiprotein complex this CDK- cyclin pair belongs
to, being the binding site for MED12 or MED13. Since CDK8 aso phosphorylates
other substrates like activators, repressors, TFIID and the Mediator itself (Chi et al.,
2001; Nelson et al., 2003; Vincent et al., 2001, Liu et al., 2004, Hallberg et al., 2004)
regulation of substrate specificity might – analogous to CDK7 regulation – depend on
the macromolecular context.  Involvement of the groove in multiprotein complex
assembly would explain its specific presence in Cyclin C and absence from Cyclin H.
However, it has to be mentioned that a conserved though much smaller patch could
also be identified for Cyclin H, located on the C-terminal cyclin repeat and facing the
kinase. Several experiments (not shown) were performed to proof binding of the CTD
to Cyclin C including GST-pulldown assays with recombinant GST-CTD fusion
protein, microcalorimetry with Cyclin C and a two-repeat CTD peptide, and
cocrystallization and soaking assays with Cyclin C crystals. Although results were to
some extend promising, they could not bring about a definite answer as the obtained
signals in all experiments were only slightly above background levels, thus lacking
statistical significance. A rather weak binding of the CTD to Cyclin C -
microcalorimetry data point to a Kd of around 5 "M - is on the other hand not
surprising for an interaction that has to be transient for function. In cocrystallization
experiments some additional density was observed in the Fo-Fc map located close to
the specific groove and to a cluster of histidines close to the kinase interface. One
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way to improve these results and increase the potentially low occupancy in the
crystal resulting from weak interaction could be a direct fusion of a CTD repeat to the
Cyclin C molecule. Additional density resulting from a well-defined interaction would
then strongly support a hypothesis of Cyclin C binding the CTD rather then other
substrates or Mediator subunits.
2.6. The CDK8/Cyclin C module and its role in Mediator function
The CDK8/Cyclin C module is variably present in different yeast Mediator
preparations (Borggrefe et al., 2002; Samuelsen et al., 2003), RNA Pol II was shown
to interact only with Mediator lacking the CDK8/Cyclin C module (Samuelsen et al.,
2003) and similar observations have been made for mammalian Mediator (Naar et
al., 2002; Wang et al., 2001). Since Mediator containing the module represses basal
transcription in vitro (Spahr et al., 2003; Taatjes et al., 2002) whereas Mediator
lacking it has a stimulatory effect (Kim et al., 1994), presence of the CDK8/Cyclin C
module might well provide a switch from repression to activation during transcription
initiation (Bjorklund and Gustafsson, 2005). It was recently suggested that
corresponding forms of Mediator might be recruited by activators and repressors to
regulatory sequences rather than to the promoter itself, whereas RNA Pol II and
GTFs are recruited to the promoter 2-3 min later (Bryant and Ptashne, 2003)
contradicting the proposition of a preformed holoenzyme complex (Bjorklund and
Gustafsson, 2005; Malik and Roeder, 2005).
Conformational changes within Mediator that have been observed, and for
which structural evidence has been presented (Baumli et al., 2005), might trigger a
mechanism in which CDK8/Cyclin C containing Mediator is unable to bind RNA Pol II
and thereby inhibits transcription. If dissociation of the CDK8/Cyclin C module was to
confer conformational changes in the Mediator it should bind in the vicinity of
subunits that have so far been implied in this movement. Indeed, contacts between
kinase and middle module (MED1 and MED4) have been shown (Kang et al., 2001)
and an interaction between Srb9 and MED17 (Srb4) has recently been described
(Guglielmi et al., 2004). In addition, the tail module serves as a substrate for CDK8,
MED2 is a phosphorylation target (Hallberg et al., 2004).
When electron microscopy data of Mediator with and without the CDK8/Cyclin
C module become available it will be very interesting to determine the position and
thus maybe function of the CDK- cyclin pair by docking the crystal structure and the
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model into the density. This should also answer the questions whether the
CDK8/Cyclin C module is involved in conformational changes of Mediator.
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